UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/077,267	10/22/2020	1673	0.00	37JD-199059-US13	12	12

CONFIRMATION NO. 4237

FILING RECEIPT

117796
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626

OC000000121686781

Date Mailed: 12/03/2020

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Jinfa Du, Redwood City, CA;
Dhanapalan Nagarathnam, Bethany, CT;
Michael Joseph Sofia, Doylestown, PA;
Peiyuan Wang, San Mateo, CA;

Applicant(s)

GILEAD PHARMASSET LLC, FOSTER CITY, CA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 16/817,318 03/12/2020 ABN
which is a CON of 16/516,192 07/18/2019 ABN
which is a CON of 16/169,878 10/24/2018 ABN
which is a CON of 15/411,506 01/20/2017 PAT 10183037
which is a CON of 14/656,546 03/12/2015 PAT 9585906
which is a CON of 14/013,237 08/29/2013 PAT 9085573
which is a CON of 13/609,614 09/11/2012 PAT 8580765
which is a CON of 13/099,671 05/03/2011 PAT 8334270
which is a CON of 12/053,015 03/21/2008 PAT 7964580
which claims benefit of 60/982,309 10/24/2007
and claims benefit of 60/909,315 03/30/2007

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 12/01/2020

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/077,267**

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No
Title

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 2 of 754

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 3 of 754

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 4 of 754

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Field of Invention

The present invention pertains to nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. The invention provides novel chemical compounds, and the use of these compounds alone or in combination with other antiviral agents for treating HCV infection.

Background

Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. There are an estimated 4.5 million infected people in the United States alone, according to the U.S. Center for Disease Control. According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring. Current treatments for HCV infection, which are restricted to immunotherapy

with recombinant interferon-α alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit. Moreover, there is no established vaccine for HCV. Consequently, there is an urgent need for improved therapeutic agents that effectively combat chronic HCV infection.

The HCV virion is an enveloped positive-strand RNA virus with a single oligoribonucleotide genomic sequence of about 9600 bases which encodes a polyprotein of about 3,010 amino acids. The protein products of the HCV gene consist of the structural proteins C, E1, and E2, and the non-structural proteins NS2, NS3, NS4A and NS4B, and NS5A and NS5B. The nonstructural (NS) proteins are believed to provide the catalytic machinery for viral replication. The NS3 protease releases NS5B, the RNA-dependent RNA polymerase from the polyprotein chain. HCV NS5B polymerase is required for the synthesis of a double-stranded RNA from a single-stranded viral RNA that serves as a template in the replication cycle of HCV. Therefore, NS5B polymerase is considered to be an essential component in the HCV replication complex (K. Ishi, et al, *Heptology*, 1999, 29: 1227-1235; V. Lohmann, et al., *Virology*, 1998, 249: 108-118). Inhibition of HCV NS5B polymerase prevents formation of the double-stranded HCV RNA and therefore constitutes an attractive approach to the development of HCV-specific antiviral therapies.

HCV belongs to a much larger family of viruses that share many common features.

Flaviviridae Viruses

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 6 of 754

The Flaviviridae family of viruses comprises at least three distinct genera: *pestiviruses*, which cause disease in cattle and pigs; *flavivruses*, which are the primary cause of diseases such as dengue fever and yellow fever; and *hepaciviruses*, whose sole member is HCV. The flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., *J. Gen. Virol*, 1993,70,37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever (*Fields Virology*, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, PA, 1996, Chapter 31, 931-959). Flaviviruses of global concern that are associated with human disease include the Dengue Hemorrhagic Fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus (Halstead, S. B., *Rev. Infect. Dis.*, 1984, 6, 251-264; Halstead, S. B., *Science*, 239:476-481, 1988; Monath, T. P., *New Eng. J. Med*, 1988, 319, 64 1-643).

The pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. *Adv. Vir. Res.* 1992, 41, 53-98). Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide. BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.J., Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir. Res. 1992, 41, 53-98). Human pestiviruses have not been as extensively characterized as the animal pestiviruses. However, serological surveys indicate considerable pestivirus exposure in humans.

Pestiviruses and hepaciviruses are closely related virus groups within the Flaviviridae family. Other closely related viruses in this family include the GB virus A,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 7 of 754

GB virus A-like agents, GB virus-B and GB virus-C (also called hepatitis G virus, HGV). The hepacivirus group (hepatitis C virus; HCV) consists of a number of closely related but genotypically distinguishable viruses that infect humans. There are at least 6 HCV genotypes and more than 50 subtypes. Due to the similarities between pestiviruses and hepaciviruses, combined with the poor ability of hepaciviruses to grow efficiently in cell culture, bovine viral diarrhea virus (BVDV) is often used as a surrogate to study the HCV virus.

The genetic organization of pestiviruses and hepaciviruses is very similar. These positive stranded RNA viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located within approximately the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF for pestiviruses and hepaciviruses is very similar. For both the pestiviruses and hepaciviruses, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.

The NS proteins of pestiviruses and hepaciviruses share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et al., *Nature,* 1988, 333, 22; Bazan and Fletterick *Virology,*

1989,171,637-639; Gorbalenya et al., *Nucleic Acid Res.*,1989, 17, 3889-3897). Similarly, the NS5B proteins of pestiviruses and hepaciviruses have the motifs characteristic of RNA-directed RNA polymerases (Koonin, E.V. and Dolja, V.V., *Crir. Rev. Biochem. Molec. Biol.* 1993, 28, 375-430).

The actual roles and functions of the NS proteins of pestiviruses and hepaciviruses in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett, *Virology*, 1991, 184, 341-350; Bartenschlager et al., *J. Virol.* 1993, 67, 3835-3844; Eckart et al. *Biochem. Biophys. Res. Comm.* 1993,192, 399-406; Grakoui et al., *J. Virol.* 1993, 67, 2832-2843; Grakoui et al., *Proc. Natl. Acad Sci. USA* 1993, 90, 10583-10587; Hijikata et al., *J. Virol.* 1993, 67, 4665-4675; Tome et al., *J. Virol.*, 1993, 67, 4017-4026). The NS4A protein, in both cases, acts as a cofactor with the NS3 serine protease (Bartenschlager et al., *J. Virol.* 1994, 68, 5045-5055; Failla et al., *J. Virol.* 1994, 68, 3753-3760; Xu et al., *J. Virol.*, 1997, 71:53 12-5322). The NS3 protein of both viruses also functions as a helicase (Kim et al., *Biochem. Biophys. Res. Comm.*, 1995, 215, 160-166; Jin and Peterson, *Arch. Biochem. Biophys.*, 1995, 323, 47-53; Warrener and Collett, *J. Virol.* 1995, 69,1720-1726). Finally, the NS5B proteins of pestiviruses and hepaciviruses have the predicted RNA-directed RNA polymerases activity (Behrens et al., EMBO, 1996, 15, 12-22; Lechmann et al., *J. Virol.*, 1997, 71, 8416-8428; Yuan et al., *Biochem. Biophys. Res. Comm.* 1997, 232, 231-235; Hagedorn, PCT WO 97/12033; Zhong et al, *J. Virol.*, 1998, 72, 9365-9369).

Currently, there are limited treatment options for individuals infected with hepatitis C virus. The current approved therapeutic option is the use of immunotherapy with recombinant interferon-α alone or in combination with the nucleoside analog ribavirin. This therapy is limited in its clinical effectiveness and only 50% of treated patients respond to therapy. Therefore, there is significant need for more effective and novel therapies to address the unmet medical need posed by HCV infection.

A number of potential molecular targets for drug development of direct acting antivirals as anti -HCV therapeutics have now been identified including, but not limited to, the NS2-NS3 autoprotease, the N3 protease, the N3 helicase and the NS5B polymerase. The RNA-dependent RNA polymerase is absolutely essential for replication of the single-stranded, positive sense, RNA genome and this enzyme has elicited significant interest among medicinal chemists.

Inhibitors of HCV NS5B as potential therapies for HCV infection have been reviewed: Tan, S.-L., et al., *Nature Rev. Drug Discov.*, 2002, 1, 867-881; Walker, M.P. et al., *Exp. Opin. Investigational Drugs*, 2003, 12, 1269-1280; Ni, Z-J., et al., *Current Opinion in Drug Discovery and Development*, 2004, 7, 446-459; Beaulieu, P. L., et al., *Current Opinion in Investigational Drugs*, 2004, 5, 838-850; Wu, J., et al., *Current Drug Targets-Infectious Disorders*, 2003, 3, 207-219; Griffith, R.C., et al, *Annual Reports in Medicinal Chemistry*, 2004, 39, 223-237; Carrol, S., et al., *Infectious Disorders-Drug Targets*, 2006, 6, 17-29. The potential for the emergence of resistant HCV strains and the need to identify agents with broad genotype coverage supports the need for continuing efforts to identify novel and more effective nucleosides as HCV NS5B inhibitors.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 10 of 754


Nucleoside inhibitors of NS5B polymerase can act either as a non-natural substrate that results in chain termination or as a competitive inhibitor which competes with nucleotide binding to the polymerase. To function as a chain terminator the nucleoside analog must be taken up by the cell and converted *in vivo* to a triphosphate to compete for the polymerase nucleotide binding site. This conversion to the triphosphate is commonly mediated by cellular kinases which imparts additional structural requirements on a potential nucleoside polymerase inhibitor. Unfortunately, this limits the direct evaluation of nucleosides as inhibitors of HCV replication to cell-based assays capable of *in situ* phosphorylation.

In some cases, the biological activity of a nucleoside is hampered by its poor substrate characteristics for one or more of the kinases needed to convert it to the active triphosphate form. Formation of the monophosphate by a nucleoside kinase is generally viewed as the rate limiting step of the three phosphorylation events. To circumvent the need for the initial phosphorylation step in the metabolism of a nucleoside to the active triphosphate analog, the preparation of stable phosphate prodrugs has been reported. Nucleoside phosphoramidate prodrugs have been shown to be precursors of the active nucleoside triphosphate and to inhibit viral replication when administered to viral infected whole cells (McGuigan, C., et al., *J. Med. Chem.*, 1996, 39, 1748-1753; Valette, G., et al., *J. Med. Chem.*, 1996, 39, 1981-1990; Balzarini, J., et al., *Proc. National Acad Sci USA*, 1996, 93, 7295-7299; Siddiqui, A. Q., et al., *J. Med. Chem.*, 1999, 42, 4122-4128; Eisenberg, E. J., et al., *Nucleosides, Nucleotides and Nucleic Acids*, 2001, 20, 1091-1098; Lee, W.A., et al., *Antimicrobial Agents and Chemotherapy*, 2005, 49, 1898); US 2006/0241064; and WO 2007/095269.

Also limiting the utility of nucleosides as viable therapeutic agents is their sometimes poor physicochemical and pharmacokinetic properties. These poor properties can limit the intestinal absorption of an agent and limit uptake into the target tissue or cell. To improve on their properties prodrugs of nucleosides have been employed. It has been demonstrated that preparation of nucleoside phosphoramidates improves the systemic absorption of a nucleoside and furthermore, the phosphoramidate moiety of these "pronucleotides" is masked with neutral lipophilic groups to obtain a suitable partition coefficient to optimize uptake and transport into the cell dramatically enhancing the intracellular concentration of the nucleoside monophosphate analog relative to administering the parent nucleoside alone. Enzyme-mediated hydrolysis of the phosphate ester moiety produces a nucleoside monophosphate wherein the rate limiting initial phosphorylation is unnecessary.

SUMMARY OF THE INVENTION

The present invention is directed toward novel phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 13 of 754

alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -N($R^{3'}$)$_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_p$OH, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 14 of 754

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

DEFINITIONS

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

The phrase "as defined herein above" refers to the first definition provided in the Summary of the Invention.

The terms "optional" or "optionally" as used herein means that a subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optional bond" means that the bond may or may not be present, and that the description includes single, double, or triple bonds.

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R appears twice and is defined as "independently carbon or nitrogen", both R's can be carbon, both R's can be nitrogen, or one R' can be carbon and the other nitrogen.

The term "alkenyl" refers to an unsubstituted hydrocarbon chain radical having from 2 to 10 carbon atoms having one or two olefinic double bonds, preferably one olefinic double bond. The term "$C_{2\text{-}N}$ alkenyl" refers to an alkenyl comprising 2 to N

carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C_{2-10} alkenyl" refers to an alkenyl comprising 2 to 10 carbon atoms. The term "C_{2-4} alkenyl" refers to an alkenyl comprising 2 to 4 carbon atoms. Examples include, but are not limited to, vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

The term "halogenated alkenyl" refers to an alkenyl comprising at least one of F, Cl, Br, and I.


The term "alkyl" refers to an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 30 carbon atoms. The term "C_{1-M} alkyl" refers to an alkyl comprising 1 to M carbon atoms, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. The term "C_{1-4} alkyl" refers to an alkyl containing 1 to 4 carbon atoms. The term "lower alkyl" denotes a straight or branched chain hydrocarbon residue comprising 1 to 6 carbon atoms. "C_{1-20} alkyl" as used herein refers to an alkyl comprising 1 to 20 carbon atoms. "C_{1-10} alkyl" as used herein refers to an alkyl comprising 1 to 10 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl. The term (ar)alkyl or (heteroaryl)alkyl indicate the alkyl group is optionally substituted by an aryl or a heteroaryl group respectively.

The term "cycloalkyl" refers to an unsubstituted or substituted carbocycle, in which the carbocycle contains 3 to 10 carbon atoms; preferably 3 to 8 carbon atoms; more preferably 3 to 6 carbon atoms (i.e., lower cycloalkyls). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "cycloalkyl alkyl" refers to an additionally unsubstituted or substituted alkyl substituted by a lower cycloalkyl. Examples of cycloalkyl alkyls include, but are not limited to, any one of methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl that is substituted with cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "cycloheteroalkyl" refers to an unsubstituted or substituted heterocycle, in which the heterocycle contains 2 to 9 carbon atoms; preferably 2 to 7 carbon atoms; more preferably 2 to 5 carbon atoms. Examples of cycloheteroalkyls include, but are not limited to, aziridin-2-yl, *N*-C_{1-3}-alkyl-aziridin-2-yl, azetidinyl, *N*-C_{1-3}-alkyl-azetidin-m'-yl, pyrrolidin-m'-yl, *N*-C_{1-3}-alkyl-pyrrolidin-m'-yl, piperidin-m'-yl, and *N*-C_{1-3}-alkyl-piperidin-m'-yl, where m' is 2, 3, or 4 depending on the cycloheteroalkyl. Specific examples of N-C_{1-3}-alkyl-cycloheteroalkyls include, but are not limited to, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-2-yl, N-methyl-piperidin-3-yl, and N-methyl-piperidin-4-yl. In the instance of R^4, the point of attachment between the cycloheteroalkyl ring carbon and the oxygen occurs at any one of m'

The term "heterocycle" refers to an unsubstituted or substituted heterocycle containing carbon, hydrogen, and at least one of N, O, and S, where the C and N can be trivalent or tetravalent, i.e., sp^2- or sp^3-hybridized. Examples of heterocycles include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, imidazole, oxazole, piperazine, etc. In the instance of piperazine, as related to R^{10} for NR'_2, the corresponding opposite nitrogen atom of the piperazinyl is substituted by a lower alkyl represented by the following structure:



Preferably, the opposite nitrogen of the piperazinyl is substituted by a methyl group.

The term "halogenated alkyl" (or "haloalkyl") refers to an unbranched or branched chain alkyl comprising at least one of F, Cl, Br, and I. The term "C_{1-M} haloalkyl" refers to an alkyl comprising 1 to M carbon atoms that comprises at least one of F, Cl, Br, and I, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. "C_{1-3} haloalkyl" refers to a haloalkyl comprising 1 to 3 carbons and at least one of F, Cl, Br, and I. The term "halogenated lower alkyl" (or "lower haloalkyl") refers to a haloalkyl comprising 1 to 6

carbon atoms and at least one of F, Cl, Br, and I. Examples include, but are not limited to, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, dibromomethyl, diiodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2-dibromomethyl, 2-2-diiodomethyl, 3-fluoropropyl, 3-chloropropyl, 3-bromopropyl, 2,2,2-trifluoroethyl or 1,1,2,2,2-pentafluoroethyl.

The term "alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond. The term "$C_{2\text{-}N}$ alkynyl" refers to an alkynyl comprising 2 to N carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C $C_{2\text{-}4}$ alkynyl" refers to an alkynyl comprising 2 to 4 carbon atoms. The term "$C_{2\text{-}10}$ alkynyl" refers to an alkynyl comprising 2 to 10 carbons. Examples include, but are limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

The term "halogenated alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond and at least one of F, Cl, Br, and I.

The term "cycloalkyl" refers to a saturated carbocyclic ring comprising 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. The term "$C_{3\text{-}7}$ cycloalkyl" as used herein refers to a cycloalkyl comprising 3 to 7 carbons in the carbocyclic ring.

The term "alkoxy" refers to an -O-alkyl group or an –O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above. Examples of –O-alkyl groups include, but are not limited to, methoxy, ethoxy, *n*-propyloxy, *i*-propyloxy, *n*-butyloxy, *i*-butyloxy, *t*-butyloxy. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "$C_{1\text{-}10}$ alkoxy" refers to an-O-alkyl wherein alkyl is $C_{1\text{-}10}$. Examples of –O-cycloalkyl groups include, but are not limited to, -O-*c*-propyl, -O-*c*-butyl, -O-*c*-pentyl, and –O-*c*-hexyl.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 19 of 754

The term "halogenated alkoxy" refers to an –O-alkyl group in which the alkyl group comprises at least one of F, Cl, Br, and I.

The term "halogenated lower alkoxy" refers to an –O-(lower alkyl) group in which the lower alkyl group comprises at least one of F, Cl, Br, and I.

The term "amino acid" includes naturally occurring and synthetic α, β γ or δ amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In a preferred embodiment, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-argininyl or β-histidinyl. When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of α, β γ or δ glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.

The term "aminoacyl" includes N,N-unsubstituted, N,N-monosubstituted, and N,N-disubstituted derivatives of naturally occurring and synthetic α, β γ or δ amino acyls, where the amino acyls are derived from amino acids. The amino-nitrogen can be substituted or unsubstituted. When the amino-nitrogen is substituted, the nitrogen is either mono- or di-substituted, where the substituent bound to the amino-nitrogen is a lower alkyl or an alkaryl. In the instance of its use for Y, the expression "O(aminoacyl)" is used. It is understood that the C3' carbon of the ribose is bound to the oxygen "O", which is then bound to the carbonyl carbon of the aminoacyl.

The terms "alkylamino" or "arylamino" refer to an amino group that has one or two alkyl or aryl substituents, respectively.

The term "protected," as used herein and unless otherwise defined, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl, CH_3, CH_2-alkyl, CH_2-alkenyl, CH_2Ph, CH_2-aryl, CH_2O-alkyl, CH_2O-aryl, SO_2-alkyl, SO_2-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

The term "aryl," as used herein, and unless otherwise specified, refers to substituted or unsubstituted phenyl (Ph), biphenyl, or naphthyl, preferably the term aryl refers to substituted or unsubstituted phenyl. The aryl group can be substituted with one or more moieties selected from among hydroxyl, F, Cl, Br, I, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in T.W. Greene and P.G. M. Wuts, "Protective Groups in Organic Synthesis," 3rd ed., John Wiley & Sons, 1999.

The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent, such as benzyl. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.

The term "di(lower alkyl)amino-lower alkyl" refers to a lower alkyl substituted by an amino group that is itself substituted by two lower alkyl groups. Examples include, but are not limited to, $(CH_3)_2NCH_2$, $(CH_3)_2NCH_2CH_2$, $(CH_3)_2NCH_2CH_2CH_2$, etc. The examples above show lower alkyls substituted at the terminus carbon atom with an N,N-dimethyl-amino substituent. These are intended as examples only and are not intended to limit the meaning of the term "di(lower alkyl)amino-lower alkyl" so as to require the same. It is contemplated that the lower alkyl chain can be substituted with an N,N-di(lower alkyl)-amino at any point along the chain, e.g., CH_3CH(N-(lower alkyl)$_2$)CH_2CH_2.

The term "halo," as used herein, includes chloro, bromo, iodo and fluoro.

The term "acyl" refers to a substituent containing a carbonyl moiety and a non-carbonyl moiety. The carbonyl moiety contains a double-bond between the carbonyl carbon and a heteroatom, where the heteroatom is selected from among O, N and S. When the heteroatom is N, the N is substituted by a lower alkyl. The non-carbonyl moiety is selected from straight, branched, and cyclic alkyl, which includes, but is not limited to, a straight, branched, or cyclic C_{1-20} alkyl, C_{1-10} alkyl, or lower alkyl; alkoxyalkyl, including methoxymethyl; aralkyl, including benzyl; aryloxyalkyl, such as phenoxymethyl; or aryl, including phenyl optionally substituted with halogen (F, Cl, Br, I), hydroxyl, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy, sulfonate esters, such as alkyl or aralkyl sulphonyl, including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. When at least one aryl group is present in the non-carbonyl moiety, it is preferred that the aryl group comprises a phenyl group.

The term "lower acyl" refers to an acyl group in which the non-carbonyl moiety is lower alkyl.

The term "purine" or "pyrimidine" base includes, but is not limited to, adenine, N^6-alkylpurines, N^6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N^6-benzylpurine, N^6-halopurine, N^6-vinylpurine, N^6-acetylenic purine, N^6-acyl purine, N^6-hydroxyalkyl purine, N^6-allcylaminopurine, N^6-thioallcyl purine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C^5-alkylpyrimidines, C^5-benzylpyrimidines, C^5-halopyrimidines, C^5-vinylpyrimidine, C^5-acetylenic pyrimidine, C^5-acyl pyrimidine, C^5-hydroxyalkyl purine, C^5-amidopyrimidine, C^5-cyanopyrimidine, ,C^5-iodopyrimidine, C^6-lodo-pyrimidine, C^5-Br-vinyl pyrimidine, C^6-Br-vinyl pyrimidine, C^5-nitropyrimidine, C^5-amino-pyrimidine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 22 of 754


hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, and *t*-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.

The term "tautomerism" and "tautomers" have their accepted plain meanings.

The term "P*" means that the phosphorous atom is chiral and that it has a corresponding Cahn-Ingold-Prelog designation of "R" or "S" which have their accepted plain meanings. It is contemplated that compounds of the formula I are racemic because the chirality at phosphorous. Applicants contemplate use of the racemate and/or the resolved enantiomers. In some instances, an asterisk does not appear next to the phosphoroamidate phosphorous atom. In these instances, it is understood that the phosphorous atom is chiral and that one of ordinary skill understands this to be so unless the substituents bound to the phosphorous exclude the possibility of chirality at phosphorous, such as in $P(O)Cl_3$.

DETAILED DESCRIPTION OF THE INVENTION

An aspect of the invention is directed to a compound, its salts, hydrates, solvates, crystalline forms, and the like represented by formula I:



wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are

optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 24 of 754

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;


(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a b c d

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 26 of 754

halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

As can be appreciated from the structure represented by formula **I** above, there are myriad ways to express the several embodiments and aspects of each embodiment of the present invention. As seen below, the inventors have disclosed certain embodiments directed to the compound of formula **I**, each having several aspects, based on the identity of the modified purine or pyrimidine base. This is not intended to be an explicit or implicit admission that the three embodiments are independent or distinct nor should it be interpreted as such. Rather, it is intended to convey information so that the full breadth of the present invention can be understood. Furthermore, the following embodiments, and aspects thereof, are not meant to be limiting on the full breadth of the invention as recited by the structure of formula **I**.

A first embodiment of the invention is directed to a compound represented by formula **I-1**:



I-1

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 27 of 754

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 28 of 754

Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)-amino, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4}

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 29 of 754

alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A first aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, vinyl, N_3, CN, Cl, Br, F, I, O(C_{1-6} acyl), O(C_{1-4} alkyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-4} haloalkyl, O(aminoacyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, or N(C_{1-4} acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A second aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 31 of 754

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a C_{1-3} alkyl, a C_{1-3} alkoxy, F, Cl, Br, I, nitro, cyano, and a C_{1-3} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A third aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl'; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fourth aspect of the first embodiment is directed to a compound represented by formula **I-2**



I-2

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and and $N(C(O)(CH_2)_sCH_3$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fifth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 36 of 754

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A sixth aspect of the first embodiment is directed to a compound represented by formula **I-2**

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 37 of 754

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, or N_3, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A seventh aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 38 of 754

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

An eighth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;


(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A second embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **b** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, R^7, and $R^8$are defined in the Summary of the Invention section above.

A first aspect of the second embodiment is directed to a compound represented by

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 40 of 754

formula **I-3**



I-3

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are

$(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl),

$S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-4}$ acyl)$_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The second aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi)

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 43 of 754

R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, vinyl, N_3, CN, Cl, Br, F, I, O(C_{1-6} acyl), O(C_{1-4} alkyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The third aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a C_{1-3} alkyl, a C_{1-3} alkoxy, F, Cl, Br, I, nitro, cyano, and a C_{1-3} haloalkyl;

(b) R^2 is hydrogen, CH_3, R^{3a} or R^{3b} and R^2 together are $(CH_2)_3$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b} are as defined herein;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 45 of 754

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The fourth aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -

$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The fifth aspect of the second embodiment is directed to a compound represented by formula **I-4**



I-4

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl,

The sixth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The seventh aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;

The eighth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The ninth aspect of the second embodiment is directed to a compound represented by formula **I-4**

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 51 of 754

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;


(h) Y is OH, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

A third embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **c** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, Z, R^{10}, R^{11}, and R^{12} are defined in the Summary of the Invention section above; with the proviso that R^{11} is not H.

A first aspect of the third embodiment is directed to a compound represented by formula **I-5**

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 52 of 754



I-5

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is from H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F,

Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A second aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 56 of 754

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fourth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 58 of 754

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 59 of 754

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A sixth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R'.

A seventh aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

An eighth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A ninth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 63 of 754

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, or N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;


(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A tenth aspect of the third embodiment is directed to a compound represented by formula **I-6**



I-6

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R'.

An eleventh aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 67 of 754

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A twelvth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 68 of 754

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is a H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A thirteenth aspect of the third embodiment is directed to a compound represented

by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fourteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 72 of 754

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R'.

An sixteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 74 of 754

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A seventeenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

An eighteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 76 of 754

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R'.

A nineteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 78 of 754

A fourth embodiment of the invention is directed to a compound represented by formula I in which the base is a structure represented by formula **c** above, where R^{11} is H and R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

A first aspect of the fourth embodiment is directed to a compound represented by formula **I-7**



I-7

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -

$(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A second aspect of the fourth embodiment is directed to a compound represented by formula **I**-7

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 82 of 754

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 83 of 754

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A fourth aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 84 of 754

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

A fifth aspect of the fourth embodiment is directed to a compound represented by formula I-7

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R',


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A sixth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 86 of 754



I-8

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl),

$OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A seventh aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R'; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

An eighth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl , N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A ninth aspect of the fourth embodiment is directed to a compound represented by

formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A tenth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fifth embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **d** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

The first aspect of the fifth embodiment is directed to a compound represented by formula **I-9**



I-9

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$

alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$.

A second aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

A third aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 97 of 754

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 N_3, OCH_3, or $OC(O)CH_3$;

A fourth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 98 of 754

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A fifth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;


(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A sixth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**



I-10

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

A seventh aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 101 of 754

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3; and

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3.

An eighth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

A ninth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 102 of 754

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A tenth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 103 of 754

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$.

The following tables contain numeric identifiers associated with various substituent designators that should be viewed in light of the accompanying structure. These structures are contemplated species of the various aspects of the disclosed embodiments and are not intended to be limiting on full breadth of the contemplated compound represented by the structure of formula **I**. However, it is contemplated that any one of the exemplified nucleoside bases can be used in combination with any one of contemplated species that specify a particular combination of R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y. In each of the presented tables, the phosphoramidate substituent containing the substituents R^{3a} and R^{3b} are depicted without reference to stereochemical structure (*cf.* structures **I-1**, **I-3**, **I-5**, **I-7**, and **I-9** above). It is contemplated that the compounds recited below embody compounds in which R^{3a} projects toward the viewer while R^{3b} projects away from the viewer (cf. structures **I-2**, **I-4**, **I-6**, **I-8**, and **I-10**). Moreover, it is contemplated that the compounds recited below also embody compounds in which R^{3a} projects away from the viewer while R^{3b} projects towards the viewer. Not meant to be limiting, however, it is contemplated that preferred compounds are those in which R^{3a} projects towards the viewer and R^{3b} projects away from the viewer such that the natural L-amino acid (S)-configuration is presented. Additionally, the inventors recognize that the phosphorus atom of the phosphoramidate moiety is another source of chirality. Although the structures below do not specifically depict chirality at phosphorus, the inventors recognize that stereochemical configurations are possible such that in a staggered (or zig-zag) line structure the oxo-substitutent projects towards the viewer

while the OR^1 substitutent projects away from the viewer, and vice versa, i.e., where the Cahn-Ingold-Prelog stereochemical designation of phosphorous is either R or S. Therefore, the structures below include all possible stereochemical configurations possible for phosphorus.



II

Table II-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-1-1	CH_3	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-8	CH_3	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-1	Et	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-2	Et	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-8	Et	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-1	Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 106 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-8	Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 107 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 108 of 754

Table II-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-11-1	CH_3	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-2	CH_3	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-8	CH_3	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-12-1	Et	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-2	Et	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-8	Et	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-13-1	^iPr	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-2	^iPr	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-3	^iPr	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-4	^iPr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-5	^iPr	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-6	^iPr	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-7	^iPr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-8	^iPr	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 109 of 754

Table II-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-14-1	^{t}Bu	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-8	^{t}Bu	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-15-1	Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-2	Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-8	Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 110 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-17-1	p-F-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-8	p-F-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 111 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-20-1	p-I-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-8	p-I-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-1	Et	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 112 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-8	Et	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 113 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 114 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-31.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 115 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-32-1	Et	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-8	Et	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 116 of 754

Table II-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 117 of 754

Table II-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 118 of 754

Table II-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-41-1	CH_3	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-8	CH_3	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-42-1	Et	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-2	Et	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-8	Et	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 119 of 754

Table II-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-45-1	Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-2	Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-8	Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 120 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 121 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 122 of 754



III

Table III-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 124 of 754

Table III-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 125 of 754

Table III-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 126 of 754

Table III-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-12-1	Et	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-8	Et	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 127 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-15-1	Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-8	Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 128 of 754

Table III-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 129 of 754

Table III-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 130 of 754

Table III-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 131 of 754

Table III-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 132 of 754

Table III-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 133 of 754

Table III-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 134 of 754

Table III-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 135 of 754

Table III-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 136 of 754

Table III-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-42-1	Et	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-8	Et	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 137 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 138 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 139 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



IV

Table IV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-1	CH_3	H	H	H	CH_3	H	F	F	OH	H	H	NH_2

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-8	CH_3	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-2-1	Et	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-8	Et	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-4.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 141 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-5-1	Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-8	Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 142 of 754

Table IV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 143 of 754

Table IV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-11-1	CH_3	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-11-8	CH_3	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-12-1	Et	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-12-2	Et	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-12-8	Et	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 144 of 754

Table IV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 145 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-15-1	Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-15-2	Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-15-8	Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 146 of 754

Table IV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 148 of 754

Table IV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 149 of 754

Table IV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 151 of 754

Table IV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 152 of 754

Table IV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-41-1	CH_3	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-41-8	CH_3	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-42-1	Et	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-42-2	Et	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-42-8	Et	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 155 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-45-1	Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-45-8	Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 156 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table IV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 157 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



V

Table V-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-1-1	CH_3	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-1-8	CH_3	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-1	Et	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 158 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-2-8	Et	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 159 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-5-1	Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-5-8	Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 160 of 754

Table V-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-11-1	CH_3	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-11-8	CH_3	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-12-1	Et	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-12-2	Et	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-12-8	Et	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-15-1	Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-15-2	Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-15-8	Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 163 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 164 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 165 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 166 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 167 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-31.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 168 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 169 of 754

Table V-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 170 of 754

Table V-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 171 of 754

Table V-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-41-1	CH_3	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-41-8	CH_3	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-42-1	Et	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-42-2	Et	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-42-8	Et	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-45-1	Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-45-8	Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 173 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 174 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 175 of 754



VI

Table VI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H
VI-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H
VI-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 176 of 754

Table VI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H
VI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H
VI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 177 of 754

Table VI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 178 of 754

Table VI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-11-1	CH_3	H	H	H	Et	H	F	H	OH	H	H
VI-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H
VI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 179 of 754

Table VI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-12-1	Et	H	H	H	Et	H	F	H	OH	H	H
VI-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H
VI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-12-8	Et	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH	H	H
VI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH	H	H
VI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H
VI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H
VI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H
VI-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 181 of 754

Table VI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 183 of 754

Table VI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 184 of 754

Table VI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 185 of 754

Table VI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 186 of 754

Table VI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 187 of 754

Table VI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 188 of 754

Table VI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-41-1	CH_3	H	H	H	Bz	H	F	H	OH	H	H
VI-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-41-8	CH_3	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-42-1	Et	H	H	H	Bz	H	F	H	OH	H	H
VI-42-2	Et	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-42-8	Et	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH	H	H
VI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH	H	H
VI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 190 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-45-1	Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-45-8	Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 191 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



VII

Table VII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H	NH_2

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 195 of 754

Table VII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 196 of 754

Table VII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-11-1	CH_3	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-12-1	Et	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-12-8	Et	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-13-1	^iPr	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-13-2	^iPr	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-13-3	^iPr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-4	^iPr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-5	^iPr	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-13-6	^iPr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-13-7	^iPr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-13-8	^iPr	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 197 of 754

Table VII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 198 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 199 of 754

Table VII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 202 of 754

Table VII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 203 of 754

Table VII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 205 of 754

Table VII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 206 of 754

Table VII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-41-1	CH_3	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-41-8	CH_3	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-42-1	Et	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-42-2	Et	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-42-8	Et	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-45-1	Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-45-8	Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 208 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 209 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 210 of 754



VIII

Table VIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-1-1	CH_3	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-8	CH_3	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-2-1	Et	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-2-2	Et	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-8	Et	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-5-1	Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-8	Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 212 of 754

Table VIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 213 of 754

Table VIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-11-1	CH_3	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-11-2	CH_3	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-11-8	CH_3	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 214 of 754

Table VIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-12-1	Et	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-12-2	Et	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-12-8	Et	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-13-1	^{i}Pr	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-13-8	^{i}Pr	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-14-1	^{t}Bu	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-14-8	^{t}Bu	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 215 of 754

Table VIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-15-1	Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-15-2	Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-15-8	Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-17-1	p-F-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-17-8	p-F-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 216 of 754

Table VIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-20-1	p-I-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-20-8	p-I-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 217 of 754

Table VIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-22-1	Et	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-8	Et	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 218 of 754

Table VIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 219 of 754

Table VIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 220 of 754

Table VIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-32-1	Et	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-8	Et	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 221 of 754

Table VIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 222 of 754

Table VIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 223 of 754

Table VIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-41-1	CH_3	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-41-8	CH_3	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 224 of 754

Table VIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-42-1	Et	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-42-2	Et	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-42-8	Et	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 225 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-45-1	Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-45-2	Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-45-8	Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 226 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table VIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 227 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



IX

Table IX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-5.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 229 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 230 of 754

Table IX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 231 of 754

Table IX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH	H	H
IX-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-12-1	Et	H	H	H	Et	H	CH_3	F	OH	H	H
IX-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-12-8	Et	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-13-1	^iPr	H	H	H	Et	H	CH_3	F	OH	H	H
IX-13-2	^iPr	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-13-3	^iPr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-13-4	^iPr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-13-5	^iPr	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-13-6	^iPr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-13-7	^iPr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-13-8	^iPr	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 232 of 754

Table IX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH	H	H
IX-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-15-1	Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-15-8	Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 233 of 754

Table IX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 234 of 754

Table IX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 235 of 754

Table IX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 236 of 754

Table IX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 237 of 754

Table IX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 238 of 754

Table IX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 239 of 754

Table IX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 241 of 754

Table IX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-42-1	Et	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-42-8	Et	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 242 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 243 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 244 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



X

Table X-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-1-1	CH_3	H	H	H	CH_3	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 245 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-1-8	CH_3	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-2-1	Et	H	H	H	CH_3	H	F	F	OH	H	H
X-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-2-8	Et	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-3-1	^iPr	H	H	H	CH_3	H	F	F	OH	H	H
X-3-2	^iPr	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-3-3	^iPr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-3-4	^iPr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-3-5	^iPr	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-3-6	^iPr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-3-7	^iPr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-3-8	^iPr	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH	H	H
X-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-5-1	Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-5-8	Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 247 of 754

Table X-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 248 of 754

Table X-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-11-1	CH_3	H	H	H	Et	H	F	F	OH	H	H
X-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH	H	H
X-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-11-8	CH_3	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-12-1	Et	H	H	H	Et	H	F	F	OH	H	H
X-12-2	Et	H	H	CH_3	Et	H	F	F	OH	H	H
X-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-12-8	Et	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 249 of 754

Table X-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH	H	H
X-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH	H	H
X-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH	H	H
X-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH	H	H
X-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-15-1	Ph	H	H	H	Et	H	F	F	OH	H	H
X-15-2	Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-15-8	Ph	*	H	*	Et	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 250 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH	H	H
X-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH	H	H
X-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH	H	H
X-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 251 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH	H	H
X-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
X-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH	H
X-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH	H
X-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H
X-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H
X-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H
X-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H
X-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H
X-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 252 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 254 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 255 of 754

Table X-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 256 of 754

Table X-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 257 of 754

Table X-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 258 of 754

Table X-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-41-1	CH_3	H	H	H	Bz	H	F	F	OH	H	H
X-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH	H	H
X-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-41-8	CH_3	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 259 of 754

Table X-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-42-1	Et	H	H	H	Bz	H	F	F	OH	H	H
X-42-2	Et	H	H	CH_3	Bz	H	F	F	OH	H	H
X-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-42-8	Et	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH	H	H
X-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH	H	H
X-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH	H	H
X-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH	H	H
X-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 260 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-45-1	Ph	H	H	H	Bz	H	F	F	OH	H	H
X-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-45-8	Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 261 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XI

Table XI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-1-1	CH_3	H	H	H	CH_3	H	H	F	OH	H	H
XI-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-1-8	CH_3	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-2-1	Et	H	H	H	CH_3	H	H	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-2-8	Et	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH	H	H
XI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH	H	H
XI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 264 of 754

Table XI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-5-1	Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-5-8	Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 265 of 754

Table XI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-11-1	CH_3	H	H	H	Et	H	H	F	OH	H	H
XI-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH	H	H
XI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-11-8	CH_3	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-12-1	Et	H	H	H	Et	H	H	F	OH	H	H
XI-12-2	Et	H	H	CH_3	Et	H	H	F	OH	H	H
XI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-12-8	Et	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH	H	H
XI-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH	H	H
XI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH	H	H
XI-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH	H	H
XI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-15-1	Ph	H	H	H	Et	H	H	F	OH	H	H
XI-15-2	Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-15-8	Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 268 of 754

Table XI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 269 of 754

Table XI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 270 of 754

Table XI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 272 of 754

Table XI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 273 of 754

Table XI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 274 of 754

Table XI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 275 of 754

Table XI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 276 of 754

Table XI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-41-1	CH_3	H	H	H	Bz	H	H	F	OH	H	H
XI-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-41-8	CH_3	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-42-1	Et	H	H	H	Bz	H	H	F	OH	H	H
XI-42-2	Et	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-42-8	Et	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH	H	H
XI-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 277 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH	H	H
XI-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-45-1	Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-45-8	Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 278 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 279 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XII

Table XII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-1-1	CH_3	H	H	H	CH_3	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 280 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-1-2	CH_3	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-1-8	CH_3	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-2-1	Et	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-2-2	Et	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-2-5	Et	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-2-8	Et	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-3-1	^{i}Pr	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-3-2	^{i}Pr	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-3-8	^{i}Pr	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 281 of 754

Table XII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-4-1	^{t}Bu	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-4-8	^{t}Bu	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-5-1	Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-5-2	Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-5-8	Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-6-1	p-Me-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-6-8	p-Me-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 282 of 754

Table XII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-7-1	p-F-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-7-20	p-F-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-9-1	p-Br-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-9-20	p-Br-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 283 of 754

Table XII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-10-1	p-I-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-10-8	p-I-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-11-1	CH_3	H	H	H	Et	N_3	F	F	OH	H	H
XII-11-2	CH_3	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-11-5	CH_3	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-11-8	CH_3	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-12-1	Et	H	H	H	Et	N_3	F	F	OH	H	H
XII-12-2	Et	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-12-5	Et	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-12-8	Et	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 284 of 754

Table XII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-13-1	^{i}Pr	H	H	H	Et	N_3	F	F	OH	H	H
XII-13-2	^{i}Pr	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-13-5	^{i}Pr	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-13-8	^{i}Pr	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-14-1	^{t}Bu	H	H	H	Et	N_3	F	F	OH	H	H
XII-14-2	^{t}Bu	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-14-8	^{t}Bu	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-15-1	Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-15-2	Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-15-5	Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-15-8	Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-16-1	p-Me-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-16-8	p-Me-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-17-1	p-F-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-17-2	p-F-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-17-8	p-F-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 286 of 754

Table XII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-18-1	p-Cl-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-18-8	p-Cl-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-19-1	p-Br-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-19-8	p-Br-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XII-20-1	p-I-Ph	H	H	H	Et	N_3	F	F	OH	H
XII-20-2	p-I-Ph	H	H	CH_3	Et	N_3	F	F	OH	H
XII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H
XII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H
XII-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H
XII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H
XII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H
XII-20-8	p-I-Ph	*	H	*	Et	N_3	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 287 of 754

Table XII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-21-1	CH_3	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-8	CH_3	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-22-1	Et	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-22-2	Et	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-8	Et	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 288 of 754

Table XII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-25-1	Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-8	Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 289 of 754

Table XII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 290 of 754

Table XII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-31-1	CH_3	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-8	CH_3	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-32-1	Et	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-32-2	Et	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-8	Et	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 291 of 754

Table XII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-35-1	Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-8	Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 292 of 754

Table XII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-41-1	CH_3	H	H	H	Bz	N_3	F	F	OH	H	H
XII-41-2	CH_3	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-41-8	CH_3	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-42-1	Et	H	H	H	Bz	N_3	F	F	OH	H	H
XII-42-2	Et	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-42-5	Et	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-42-8	Et	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-43-1	^{i}Pr	H	H	H	Bz	N_3	F	F	OH	H	H
XII-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-43-8	^{i}Pr	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-44-1	^{t}Bu	H	H	H	Bz	N_3	F	F	OH	H	H
XII-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-44-8	^{t}Bu	*	H	*	Bz	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 295 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-45-1	Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-45-2	Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-45-5	Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-45-8	Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-46-1	p-Me-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-46-8	p-Me-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-47-1	p-F-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 296 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-47-8	p-F-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-48-1	p-Cl-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-48-8	p-Cl-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-49-1	p-Br-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-49-8	p-Br-Ph	*	H	*	Bz	N_3	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-50-1	p-I-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-50-8	p-I-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XIII

Table XIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-1-1	CH_3	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-1-2	CH_3	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-1-8	CH_3	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-2-1	Et	H	H	H	CH_3	N_3	H	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-2-2	Et	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-2-5	Et	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-2-8	Et	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-3-1	^{i}Pr	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-3-2	^{i}Pr	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-3-8	^{i}Pr	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-4-1	^{t}Bu	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-4-8	^{t}Bu	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 299 of 754

Table XIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-5-1	Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-5-2	Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-5-8	Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-6-1	p-Me-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-6-8	p-Me-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-7-1	p-F-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-7-20	p-F-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 300 of 754

Table XIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-9-1	p-Br-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-9-20	p-Br-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-10-1	p-I-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-10-8	p-I-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 301 of 754

Table XIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-11-1	CH_3	H	H	H	Et	N_3	H	F	OH	H	H
XIII-11-2	CH_3	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-11-5	CH_3	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-11-8	CH_3	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-12-1	Et	H	H	H	Et	N_3	H	F	OH	H	H
XIII-12-2	Et	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-12-5	Et	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-12-8	Et	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-13-1	^iPr	H	H	H	Et	N_3	H	F	OH	H	H
XIII-13-2	^iPr	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-13-3	^iPr	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-13-4	^iPr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-13-5	^iPr	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-13-6	^iPr	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-13-7	^iPr	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-13-8	^iPr	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 302 of 754

Table XIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-14-1	^{t}Bu	H	H	H	Et	N_3	H	F	OH	H	H
XIII-14-2	^{t}Bu	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-14-8	^{t}Bu	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-15-1	Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-15-2	Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-15-5	Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-15-8	Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-16-1	p-Me-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-16-8	p-Me-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 303 of 754

Table XIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-17-1	p-F-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-17-2	p-F-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-17-8	p-F-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-18-1	p-Cl-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-18-8	p-Cl-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-19-1	p-Br-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-19-8	p-Br-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 304 of 754

Table XIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-20-1	p-I-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-20-2	p-I-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-20-8	p-I-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-21-1	CH_3	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-8	CH_3	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-22-1	Et	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-2	Et	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-8	Et	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-25-1	Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-8	Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 307 of 754

Table XIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-31-1	CH_3	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-8	CH_3	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 308 of 754

Table XIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-32-1	Et	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-2	Et	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-8	Et	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 309 of 754

Table XIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-35-1	Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-8	Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 310 of 754

Table XIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-41-1	CH_3	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-41-2	CH_3	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-41-8	CH_3	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-42-1	Et	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-42-2	Et	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-42-5	Et	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-42-8	Et	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-43-1	^{i}Pr	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-43-8	^{i}Pr	*	H	*	Bz	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 312 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-44-1	^{t}Bu	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-44-8	^{t}Bu	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-45-1	Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-45-2	Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-45-5	Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-45-8	Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-46-1	p-Me-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 313 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-46-8	p-Me-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-47-1	p-F-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-47-8	p-F-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-48-1	p-Cl-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-48-8	p-Cl-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-49-1	p-Br-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-49-8	p-Br-Ph	*	H	*	Bz	N_3	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-50-1	p-I-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-50-8	p-I-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XIV

Table XIV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-1-1	CH_3	H	H	H	CH_3	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 315 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-1-2	CH_3	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-1-8	CH_3	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-2-1	Et	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-2-2	Et	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-2-5	Et	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-2-8	Et	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-3-1	^iPr	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-3-2	^iPr	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-3-3	^iPr	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-3-4	^iPr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-3-5	^iPr	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-3-6	^iPr	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-3-7	^iPr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-3-8	^iPr	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 316 of 754

Table XIV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-4-1	^{t}Bu	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-4-8	^{t}Bu	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-5-1	Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-5-2	Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-5-8	Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-6-1	p-Me-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-6-8	p-Me-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 317 of 754

Table XIV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-7-1	p-F-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-7-20	p-F-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-9-1	p-Br-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-9-20	p-Br-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 318 of 754

Table XIV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-10-1	p-I-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-10-8	p-I-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-11-1	CH_3	H	H	H	Et	N_3	F	H	OH	H	H
XIV-11-2	CH_3	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-11-5	CH_3	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-11-8	CH_3	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-12-1	Et	H	H	H	Et	N_3	F	H	OH	H	H
XIV-12-2	Et	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-12-5	Et	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-12-8	Et	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 319 of 754

Table XIV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-13-1	^{i}Pr	H	H	H	Et	N_3	F	H	OH	H	H
XIV-13-2	^{i}Pr	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-13-5	^{i}Pr	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-13-8	^{i}Pr	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-14-1	^{t}Bu	H	H	H	Et	N_3	F	H	OH	H	H
XIV-14-2	^{t}Bu	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-14-8	^{t}Bu	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-15-1	Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-15-2	Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-15-5	Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-15-8	Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-16-1	p-Me-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-16-8	p-Me-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-17-1	p-F-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-17-2	p-F-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-17-8	p-F-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-18-1	p-Cl-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-18-8	p-Cl-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 321 of 754

Table XIV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-19-1	p-Br-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-19-8	p-Br-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-20-1	p-I-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-20-2	p-I-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-20-8	p-I-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-21-1	CH_3	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-8	CH_3	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-22-1	Et	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-2	Et	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-8	Et	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 323 of 754

Table XIV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-25-1	Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-8	Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 324 of 754

Table XIV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-31-1	CH_3	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-8	CH_3	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-32-1	Et	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-2	Et	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-8	Et	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 326 of 754

Table XIV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-35-1	Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-8	Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 327 of 754

Table XIV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-41-1	CH_3	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-41-2	CH_3	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-41-8	CH_3	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-42-1	Et	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-42-2	Et	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-42-5	Et	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-42-8	Et	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 329 of 754

Table XIV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-43-1	^{i}Pr	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-43-8	^{i}Pr	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-44-1	^{t}Bu	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-44-8	^{t}Bu	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-45-1	Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-45-2	Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-45-5	Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-45-8	Ph	*	H	*	Bz	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 330 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-46-1	p-Me-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-46-8	p-Me-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-47-1	p-F-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-47-8	p-F-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-48-1	p-Cl-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 331 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-48-8	p-Cl-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-49-1	p-Br-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-49-8	p-Br-Ph	*	H	*	Bz	N_3	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-50-1	p-I-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-50-8	p-I-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 332 of 754



XV

Table XV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-1-1	CH_3	H	H	H	CH_3	F	F	H	OH	H	H
XV-1-2	CH_3	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-1-5	CH_3	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-1-8	CH_3	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-2-1	Et	H	H	H	CH_3	F	F	H	OH	H	H
XV-2-2	Et	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-2-5	Et	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-2-8	Et	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-3-1	^{i}Pr	H	H	H	CH_3	F	F	H	OH	H	H
XV-3-2	^{i}Pr	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-3-8	^{i}Pr	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-4-1	^{t}Bu	H	H	H	CH_3	F	F	H	OH	H	H
XV-4-2	^{t}Bu	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-4-8	^{t}Bu	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-5-1	Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-5-2	Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-5-5	Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-5-8	Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 334 of 754

Table XV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-6-1	p-Me-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-6-8	p-Me-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-7-1	p-F-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-7-2	p-F-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-7-20	p-F-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-8-1	p-Cl-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-8-8	p-Cl-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 335 of 754

Table XV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-9-1	p-Br-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-9-20	p-Br-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-10-1	p-I-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-10-2	p-I-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-10-8	p-I-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-11-1	CH_3	H	H	H	Et	F	F	H	OH	H	H
XV-11-2	CH_3	H	H	CH_3	Et	F	F	H	OH	H	H
XV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-11-5	CH_3	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-11-8	CH_3	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 336 of 754

Table XV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-12-1	Et	H	H	H	Et	F	F	H	OH	H	H
XV-12-2	Et	H	H	CH_3	Et	F	F	H	OH	H	H
XV-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-12-5	Et	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-12-8	Et	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-13-1	^{i}Pr	H	H	H	Et	F	F	H	OH	H	H
XV-13-2	^{i}Pr	H	H	CH_3	Et	F	F	H	OH	H	H
XV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-13-8	^{i}Pr	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-14-1	^{t}Bu	H	H	H	Et	F	F	H	OH	H	H
XV-14-2	^{t}Bu	H	H	CH_3	Et	F	F	H	OH	H	H
XV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-14-8	^{t}Bu	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 337 of 754

Table XV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-15-1	Ph	H	H	H	Et	F	F	H	OH	H	H
XV-15-2	Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-15-5	Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-15-8	Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-16-1	p-Me-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-16-2	p-Me-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-16-8	p-Me-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-17-1	p-F-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-17-2	p-F-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-17-8	p-F-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-18-1	p-Cl-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-18-2	p-Cl-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-18-8	p-Cl-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-19-1	p-Br-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-19-2	p-Br-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-19-8	p-Br-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-20-1	p-I-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-20-2	p-I-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-20-8	p-I-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 339 of 754

Table XV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-21-1	CH_3	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-21-2	CH_3	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-21-8	CH_3	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-22-1	Et	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-22-2	Et	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-22-8	Et	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-23-1	^{i}Pr	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-23-8	^{i}Pr	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 340 of 754

Table XV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-24-1	^{t}Bu	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-24-8	^{t}Bu	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-25-1	Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-25-2	Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-25-8	Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 341 of 754

Table XV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-27-1	p-F-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-27-8	p-F-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-30-1	p-I-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-30-8	p-I-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-31-1	CH_3	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-31-2	CH_3	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-31-8	CH_3	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-32-1	Et	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-32-2	Et	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-32-8	Et	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-33-1	^{i}Pr	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-33-8	^{i}Pr	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-34-1	^{t}Bu	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-34-8	^{t}Bu	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-35-1	Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-35-2	Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-35-8	Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-37-1	p-F-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-37-8	p-F-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 345 of 754

Table XV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-40-1	p-I-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-40-8	p-I-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-41-1	CH_3	H	H	H	Bz	F	F	H	OH	H	H
XV-41-2	CH_3	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-41-5	CH_3	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-41-8	CH_3	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 346 of 754

Table XV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-42-1	Et	H	H	H	Bz	F	F	H	OH	H	H
XV-42-2	Et	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-42-5	Et	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-42-8	Et	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-43-1	^{i}Pr	H	H	H	Bz	F	F	H	OH	H	H
XV-43-2	^{i}Pr	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-43-8	^{i}Pr	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-44-1	^{t}Bu	H	H	H	Bz	F	F	H	OH	H	H
XV-44-2	^{t}Bu	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-44-8	^{t}Bu	*	H	*	Bz	F	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 347 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-45-1	Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-45-2	Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-45-5	Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-45-8	Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-46-1	p-Me-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-46-2	p-Me-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-46-8	p-Me-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-47-1	p-F-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-47-2	p-F-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-47-8	p-F-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-48-1	p-Cl-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-48-8	p-Cl-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-49-1	p-Br-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-49-2	p-Br-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-49-8	p-Br-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-50-1	p-I-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-50-2	p-I-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 349 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-50-8	p-I-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XVI

Table XVI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-1-1	CH_3	H	H	H	CH_3	F	F	F	OH	H	H
XVI-1-2	CH_3	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-1-5	CH_3	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-1-8	CH_3	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-2-1	Et	H	H	H	CH_3	F	F	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-2-2	Et	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-2-5	Et	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-2-8	Et	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-3-1	^{i}Pr	H	H	H	CH_3	F	F	F	OH	H	H
XVI-3-2	^{i}Pr	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-3-8	^{i}Pr	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-4-1	^{t}Bu	H	H	H	CH_3	F	F	F	OH	H	H
XVI-4-2	^{t}Bu	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-4-8	^{t}Bu	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 351 of 754

Table XVI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-5-1	Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-5-2	Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-5-5	Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-5-8	Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-6-1	p-Me-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-6-8	p-Me-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-7-1	p-F-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-7-2	p-F-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-7-20	p-F-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-8-1	p-Cl-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-8-8	p-Cl-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-9-1	p-Br-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-9-20	p-Br-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-10-1	p-I-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-10-2	p-I-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-10-8	p-I-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-11-1	CH_3	H	H	H	Et	F	F	F	OH	H	H
XVI-11-2	CH_3	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-11-5	CH_3	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-11-8	CH_3	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-12-1	Et	H	H	H	Et	F	F	F	OH	H	H
XVI-12-2	Et	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-12-5	Et	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-12-8	Et	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-13-1	^{i}Pr	H	H	H	Et	F	F	F	OH	H	H
XVI-13-2	^{i}Pr	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-13-8	^{i}Pr	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 354 of 754

Table XVI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-14-1	^{t}Bu	H	H	H	Et	F	F	F	OH	H	H
XVI-14-2	^{t}Bu	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-14-8	^{t}Bu	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-15-1	Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-15-2	Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-15-5	Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-15-8	Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-16-1	p-Me-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-16-2	p-Me-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-16-8	p-Me-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 355 of 754

Table XVI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-17-1	p-F-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-17-2	p-F-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-17-8	p-F-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-18-1	p-Cl-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-18-2	p-Cl-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-18-8	p-Cl-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-19-1	p-Br-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-19-2	p-Br-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-19-8	p-Br-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 356 of 754

Table XVI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XVI-20-1	p-I-Ph	H	H	H	Et	F	F	F	OH	H
XVI-20-2	p-I-Ph	H	H	CH_3	Et	F	F	F	OH	H
XVI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H
XVI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H
XVI-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H
XVI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H
XVI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H
XVI-20-8	p-I-Ph	*	H	*	Et	F	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-21-1	CH_3	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-21-2	CH_3	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-21-8	CH_3	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-22-1	Et	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-22-2	Et	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-22-8	Et	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-23-1	^{i}Pr	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-23-8	^{i}Pr	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-24-1	^{t}Bu	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-24-8	^{t}Bu	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-25-1	Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-25-2	Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-25-8	Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-27-1	p-F-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-27-8	p-F-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 359 of 754

Table XVI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-30-1	p-I-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-30-8	p-I-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-31-1	CH_3	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-31-2	CH_3	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-31-8	CH_3	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-32-1	Et	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-32-2	Et	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-32-8	Et	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-33-1	^{i}Pr	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-33-8	^{i}Pr	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-34-1	^{t}Bu	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-34-8	^{t}Bu	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 361 of 754

Table XVI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-35-1	Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-35-2	Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-35-8	Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-37-1	p-F-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-37-8	p-F-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 362 of 754

Table XVI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-40-1	p-I-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-40-8	p-I-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 363 of 754

Table XVI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-41-1	CH_3	H	H	H	Bz	F	F	F	OH	H	H
XVI-41-2	CH_3	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-41-5	CH_3	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-41-8	CH_3	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-42-1	Et	H	H	H	Bz	F	F	F	OH	H	H
XVI-42-2	Et	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-42-5	Et	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-42-8	Et	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-43-1	^{i}Pr	H	H	H	Bz	F	F	F	OH	H	H
XVI-43-2	^{i}Pr	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-43-8	^{i}Pr	*	H	*	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 364 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-44-1	^{t}Bu	H	H	H	Bz	F	F	F	OH	H	H
XVI-44-2	^{t}Bu	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-44-8	^{t}Bu	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-45-1	Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-45-2	Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-45-5	Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-45-8	Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-1	p-Me-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-46-2	p-Me-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 365 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-8	p-Me-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-47-1	p-F-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-47-2	p-F-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-47-8	p-F-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-1	p-Cl-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-48-8	p-Cl-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-1	p-Br-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-49-2	p-Br-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 366 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-49-8	p-Br-Ph	*	H	*	Bz	F	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-50-1	p-I-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-50-2	p-I-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-50-8	p-I-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XVII

Table XVII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-1-1	CH_3	H	H	H	CH_3	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 367 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-1-2	CH_3	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-1-5	CH_3	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-1-8	CH_3	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-2-1	Et	H	H	H	CH_3	F	H	F	OH	H	H
XVII-2-2	Et	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-2-5	Et	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-2-8	Et	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-3-1	^{i}Pr	H	H	H	CH_3	F	H	F	OH	H	H
XVII-3-2	^{i}Pr	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-3-8	^{i}Pr	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 368 of 754

Table XVII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-4-1	^{t}Bu	H	H	H	CH_3	F	H	F	OH	H	H
XVII-4-2	^{t}Bu	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-4-8	^{t}Bu	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-5-1	Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-5-2	Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-5-5	Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-5-8	Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-6-1	p-Me-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-6-8	p-Me-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 369 of 754

Table XVII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-7-1	p-F-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-7-2	p-F-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-7-20	p-F-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-8-1	p-Cl-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-8-8	p-Cl-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-9-1	p-Br-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-9-20	p-Br-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-10-1	p-I-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-10-2	p-I-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-10-8	p-I-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-11-1	CH_3	H	H	H	Et	F	H	F	OH	H	H
XVII-11-2	CH_3	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-11-5	CH_3	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-11-8	CH_3	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-12-1	Et	H	H	H	Et	F	H	F	OH	H	H
XVII-12-2	Et	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-12-5	Et	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-12-8	Et	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 371 of 754

Table XVII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-13-1	^{i}Pr	H	H	H	Et	F	H	F	OH	H	H
XVII-13-2	^{i}Pr	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-13-8	^{i}Pr	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-14-1	^{t}Bu	H	H	H	Et	F	H	F	OH	H	H
XVII-14-2	^{t}Bu	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-14-8	^{t}Bu	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-15-1	Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-15-2	Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-15-5	Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-15-8	Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-16-1	p-Me-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-16-2	p-Me-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-16-8	p-Me-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-17-1	p-F-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-17-2	p-F-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-17-8	p-F-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-18-1	p-Cl-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-18-2	p-Cl-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-18-8	p-Cl-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-19-1	p-Br-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-19-2	p-Br-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-19-8	p-Br-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-20-1	p-I-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-20-2	p-I-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-20-8	p-I-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-21-1	CH_3	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-21-2	CH_3	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-21-8	CH_3	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 374 of 754

Table XVII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-22-1	Et	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-22-2	Et	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-22-8	Et	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-23-1	^{i}Pr	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-23-8	^{i}Pr	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-24-1	^{t}Bu	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-24-8	^{t}Bu	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 375 of 754

Table XVII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-25-1	Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-25-2	Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-25-8	Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-27-1	p-F-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-27-8	p-F-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 376 of 754

Table XVII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-30-1	p-I-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-30-8	p-I-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 377 of 754

Table XVII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-31-1	CH_3	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-31-2	CH_3	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-31-8	CH_3	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-32-1	Et	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-32-2	Et	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-32-8	Et	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-33-1	^{i}Pr	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-33-8	^{i}Pr	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 378 of 754

Table XVII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-34-1	^{t}Bu	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-34-8	^{t}Bu	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-35-1	Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-35-2	Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-35-8	Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 379 of 754

Table XVII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-37-1	p-F-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-37-8	p-F-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-40-1	p-I-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-40-8	p-I-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-41-1	CH_3	H	H	H	Bz	F	H	F	OH	H	H
XVII-41-2	CH_3	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-41-5	CH_3	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-41-8	CH_3	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-42-1	Et	H	H	H	Bz	F	H	F	OH	H	H
XVII-42-2	Et	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-42-5	Et	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-42-8	Et	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-43-1	^{i}Pr	H	H	H	Bz	F	H	F	OH	H	H
XVII-43-2	^{i}Pr	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-43-8	^{i}Pr	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-44-1	^{t}Bu	H	H	H	Bz	F	H	F	OH	H	H
XVII-44-2	^{t}Bu	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-44-8	^{t}Bu	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-45-1	Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-45-2	Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-45-5	Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-45-8	Ph	*	H	*	Bz	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 382 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-1	p-Me-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-46-2	p-Me-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-46-8	p-Me-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-47-1	p-F-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-47-2	p-F-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-47-8	p-F-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-1	p-Cl-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 383 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-8	p-Cl-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-1	p-Br-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-49-2	p-Br-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-49-8	p-Br-Ph	*	H	*	Bz	F	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-50-1	p-I-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-50-2	p-I-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-50-8	p-I-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 384 of 754



XVIII

Table XVIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-1-1	CH_3	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-8	CH_3	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-2-1	Et	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-2	Et	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-8	Et	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-5-1	Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-2	Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-8	Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 386 of 754

Table XVIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-11-1	CH_3	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-11-2	CH_3	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-11-8	CH_3	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-12-1	Et	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-12-2	Et	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-12-5	Et	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-12-8	Et	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-13-1	^{i}Pr	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-13-8	^{i}Pr	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-14-1	^{t}Bu	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-14-8	^{t}Bu	*	H	*	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 389 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-15-1	Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-15-2	Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-15-8	Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-16-1	p-Me-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-16-8	p-Me-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-17-1	p-F-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 390 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-17-8	p-F-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-19-1	p-Br-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-19-8	p-Br-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-20-1	p-I-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 391 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-20-8	p-I-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-22-1	Et	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-8	Et	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 392 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-25-1	Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-8	Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 395 of 754

Table XVIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-32-1	Et	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-8	Et	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 396 of 754

Table XVIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-35-1	Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-8	Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 398 of 754

Table XVIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-41-1	CH_3	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-41-2	CH_3	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-8	CH_3	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-42-1	Et	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-42-2	Et	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-8	Et	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-43-1	^{i}Pr	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-8	^{i}Pr	*	H	*	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 399 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-44-1	^{t}Bu	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-8	^{t}Bu	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-45-1	Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-45-2	Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-8	Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 400 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-47-1	p-F-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-8	p-F-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 401 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-50-1	p-I-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-8	p-I-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XIX

Table XIX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-1-1	CH_3	H	H	H	CH_3	OCH_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 402 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-8	CH_3	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-2-1	Et	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-2-2	Et	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-8	Et	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 403 of 754

Table XIX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-5-1	Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-5-2	Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-8	Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 405 of 754

Table XIX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-11-1	CH_3	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-11-2	CH_3	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-11-8	CH_3	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-12-1	Et	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-12-2	Et	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-12-5	Et	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-12-8	Et	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-13-1	^{i}Pr	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-13-8	^{i}Pr	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-14-1	^{t}Bu	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-14-8	^{t}Bu	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-15-1	Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-15-2	Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-15-8	Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-16-1	p-Me-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-16-8	p-Me-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-17-1	p-F-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-17-8	p-F-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-19-1	p-Br-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-19-8	p-Br-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XIX-20-1	p-I-Ph	H	H	H	Et	OCH_3	F	F	OH	H
XIX-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H
XIX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H
XIX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H
XIX-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H
XIX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H
XIX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H
XIX-20-8	p-I-Ph	*	H	*	Et	OCH_3	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 409 of 754

Table XIX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-22-1	Et	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-8	Et	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 410 of 754

Table XIX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-25-1	Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-8	Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 411 of 754

Table XIX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-32-1	Et	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-8	Et	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-35-1	Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-8	Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 414 of 754

Table XIX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-41-1	CH_3	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-41-2	CH_3	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-41-8	CH_3	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-42-1	Et	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-42-2	Et	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-42-8	Et	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-43-1	^{i}Pr	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-43-8	^{i}Pr	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-44-1	^{t}Bu	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-44-8	^{t}Bu	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-45-1	Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-45-2	Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-45-8	Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 417 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-47-1	p-F-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-47-8	p-F-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-50-1	p-I-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-50-8	p-I-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 419 of 754



XX

Table XX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-1-1	CH_3	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-1-8	CH_3	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-2-1	Et	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-2-2	Et	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-2-8	Et	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-5-1	Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-5-2	Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-5-8	Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 421 of 754

Table XX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-11-1	CH_3	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-11-2	CH_3	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-11-8	CH_3	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-12-1	Et	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-12-2	Et	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-12-5	Et	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-12-8	Et	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-13-1	^{i}Pr	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-13-8	^{i}Pr	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-14-1	^{t}Bu	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-14-8	^{t}Bu	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 424 of 754

Table XX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-15-1	Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-15-2	Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-15-8	Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-16-1	p-Me-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-16-8	p-Me-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-17-1	p-F-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-17-8	p-F-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 425 of 754

Table XX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-19-1	p-Br-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-19-8	p-Br-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-20-1	p-I-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-20-8	p-I-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 426 of 754

Table XX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-22-1	Et	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-8	Et	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 427 of 754

Table XX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-25-1	Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-8	Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 428 of 754

Table XX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-32-1	Et	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-8	Et	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 430 of 754

Table XX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-35-1	Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-8	Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 432 of 754

Table XX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-41-1	CH_3	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-41-2	CH_3	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-41-8	CH_3	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 433 of 754

Table XX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-42-1	Et	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-42-2	Et	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-42-8	Et	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-43-1	^{i}Pr	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-43-8	^{i}Pr	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-44-1	^{t}Bu	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-44-8	^{t}Bu	*	H	*	Bz	OCH_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 434 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-45-1	Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-45-2	Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-45-8	Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-47-1	p-F-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 435 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-47-8	p-F-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-50-1	p-I-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-50-8	p-I-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXI

Table XXI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXI-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXI-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH
XXI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 438 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 439 of 754

Table XXI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 440 of 754

Table XXI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXI-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXI-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXI-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 441 of 754

Table XXI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXI-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXI-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 443 of 754

Table XXI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 444 of 754

Table XXI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 445 of 754

Table XXI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 446 of 754

Table XXI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 447 of 754

Table XXI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 448 of 754

Table XXI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 449 of 754

Table XXI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 450 of 754

Table XXI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXI-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXI-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXI-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXI-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 452 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 453 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXII

Table XXII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXII-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH
XXII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXII-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH
XXII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH
XXII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 455 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXII-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 456 of 754

Table XXII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXII-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-12-1	Et	H	H	H	Et	H	F	H	OH
XXII-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 458 of 754

Table XXII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH
XXII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-15-1	Ph	H	H	H	Et	H	F	H	OH
XXII-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 459 of 754

Table XXII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 460 of 754

Table XXII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 462 of 754

Table XXII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 463 of 754

Table XXII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 464 of 754

Table XXII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH
XXII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH
XXII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH
XXII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 466 of 754

Table XXII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXII-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-42-1	Et	H	H	H	Bz	H	F	H	OH
XXII-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 468 of 754

Table XXII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXII-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-45-8	Ph	*	H	*	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 469 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 470 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-49.


№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXIII

Table XXIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXIII-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXIII-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXIII-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 473 of 754

Table XXIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 474 of 754

Table XXIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXIII-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-12-1	Et	H	H	H	Et	H	F	F	OH
XXIII-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXIII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXIII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 476 of 754

Table XXIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-15-1	Ph	H	H	H	Et	H	F	F	OH
XXIII-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXIII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 477 of 754

Table XXIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXIII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 478 of 754

Table XXIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXIII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 479 of 754

Table XXIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 480 of 754

Table XXIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 481 of 754

Table XXIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXIII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXIII-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-42-1	Et	H	H	H	Bz	H	F	F	OH
XXIII-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 486 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXIII-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XXIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 488 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXIV

Table XXIV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXIV-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXIV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXIV-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXIV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXIV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXIV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXIV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXIV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXIV-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXIV-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXIV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-12-1	Et	H	H	H	Et	H	H	F	OH
XXIV-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXIV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXIV-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXIV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXIV-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXIV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-15-1	Ph	H	H	H	Et	H	H	F	OH
XXIV-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXIV-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 494 of 754

Table XXIV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXIV-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXIV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXIV-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 495 of 754

Table XXIV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXIV-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXIV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXIV-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXIV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXIV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 497 of 754

Table XXIV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 498 of 754

Table XXIV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXIV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXIV-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXIV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXIV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 500 of 754

Table XXIV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXIV-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXIV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-42-1	Et	H	H	H	Bz	H	H	F	OH
XXIV-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXIV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXIV-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXIV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXIV-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXIV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXIV-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXIV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 504 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXIV-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXIV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXIV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 505 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXIV-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXV

Table XXV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXV-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXV-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 508 of 754

Table XXV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 509 of 754

Table XXV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXV-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXV-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXV-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXV-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXV-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 511 of 754

Table XXV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 514 of 754

Table XXV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 515 of 754

Table XXV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 516 of 754

Table XXV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 517 of 754

Table XXV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 518 of 754

Table XXV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 519 of 754

Table XXV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXV-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXV-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXV-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXV-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 521 of 754

Table XXV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXVI

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 523 of 754

Table XXVI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXVI-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH
XXVI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXVI-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXVI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-3-1	^iPr	H	H	H	CH_3	H	F	H	OH
XXVI-3-2	^iPr	H	H	CH_3	CH_3	H	F	H	OH
XXVI-3-3	^iPr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-3-4	^iPr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-3-5	^iPr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-3-6	^iPr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-3-7	^iPr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-3-8	^iPr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 524 of 754

Table XXVI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH
XXVI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXVI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXVI-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 525 of 754

Table XXVI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 526 of 754

Table XXVI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXVI-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXVI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-12-1	Et	H	H	H	Et	H	F	H	OH
XXVI-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXVI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXVI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXVI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH
XXVI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXVI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-15-1	Ph	H	H	H	Et	H	F	H	OH
XXVI-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXVI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXVI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXVI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 529 of 754

Table XXVI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXVI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXVI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXVI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXVI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXVI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXVI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 531 of 754

Table XXVI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH
XXVI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH
XXVI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH
XXVI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXVI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXVI-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXVI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-42-1	Et	H	H	H	Bz	H	F	H	OH
XXVI-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXVI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXVI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXVI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXVI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXVI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXVI-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-45-8	Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 538 of 754

Table XXVI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXVI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXVI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXVI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 539 of 754

Table XXVI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXVI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXVI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXVII

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 540 of 754

Table XXVII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXVII-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXVII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXVII-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXVII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXVII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXVII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 541 of 754

Table XXVII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXVII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXVII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXVII-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 542 of 754

Table XXVII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXVII-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXVII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-12-1	Et	H	H	H	Et	H	F	F	OH
XXVII-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXVII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXVII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXVII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXVII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXVII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-15-1	Ph	H	H	H	Et	H	F	F	OH
XXVII-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXVII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXVII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXVII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXVII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXVII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXVII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXVII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXVII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXVII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 548 of 754

Table XXVII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 549 of 754

Table XXVII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 550 of 754

Table XXVII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXVII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXVII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXVII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXVII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 552 of 754

Table XXVII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 553 of 754

Table XXVII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXVII-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXVII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-42-1	Et	H	H	H	Bz	H	F	F	OH
XXVII-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXVII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXVII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXVII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXVII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXVII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXVII-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXVII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXVII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 556 of 754

Table XXVII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXVII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXVII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXVIII

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 557 of 754

Table XXVIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXVIII-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXVIII-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXVIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 558 of 754

Table XXVIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXVIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 559 of 754

Table XXVIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 560 of 754

Table XXVIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXVIII-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXVIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-12-1	Et	H	H	H	Et	H	H	F	OH
XXVIII-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXVIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXVIII-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXVIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXVIII-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXVIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXVIII-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXVIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXVIII-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXVIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 563 of 754

Table XXVIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXVIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXVIII-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 564 of 754

Table XXVIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 565 of 754

Table XXVIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 567 of 754

Table XXVIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 568 of 754

Table XXVIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 569 of 754

Table XXVIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 570 of 754

Table XXVIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXVIII-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXVIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXVIII-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXVIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXVIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXVIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXVIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXVIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXVIII-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 572 of 754

Table XXVIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 573 of 754

Table XXVIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXIX

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 574 of 754

Table XXIX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXIX-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXIX-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXIX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 575 of 754

Table XXIX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH
XXIX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 576 of 754

Table XXIX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 577 of 754

Table XXIX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXIX-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXIX-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXIX-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXIX-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 579 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 581 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 582 of 754

Table XXIX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 583 of 754

Table XXIX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 585 of 754

Table XXIX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 586 of 754

Table XXIX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 587 of 754

Table XXIX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXIX-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 588 of 754

Table XXIX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXIX-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXIX-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXIX-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 589 of 754

Table XXIX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 590 of 754

Table XXIX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-49.


№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXX

Table XXX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXX-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH
XXX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXX-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH
XXX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH
XXX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH
XXX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXX-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 594 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXX-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-12-1	Et	H	H	H	Et	H	F	H	OH
XXX-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXX-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 596 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-15-1	Ph	H	H	H	Et	H	F	H	OH
XXX-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXX-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 597 of 754

Table XXX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXX-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXX-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXX-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXX-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 599 of 754

Table XXX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 600 of 754

Table XXX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 601 of 754

Table XXX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH
XXX-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 602 of 754

Table XXX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH
XXX-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH
XXX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 603 of 754

Table XXX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 605 of 754

Table XXX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXX-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-42-1	Et	H	H	H	Bz	H	F	H	OH
XXX-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXX-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXX-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXX-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-45-8	Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXX-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 608 of 754

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXX-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXXI

Table XXXI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXXI-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXXI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXXI-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXXI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXXI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXXI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXXI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXXI-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 611 of 754

Table XXXI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXXI-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXXI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-12-1	Et	H	H	H	Et	H	F	F	OH
XXXI-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXXI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXXI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXXI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXXI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXXI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-15-1	Ph	H	H	H	Et	H	F	F	OH
XXXI-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 614 of 754

Table XXXI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXXI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXXI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXXI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXXI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXXI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXXI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXXI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXXI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXXI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 617 of 754

Table XXXI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 619 of 754

Table XXXI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXXI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXXI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXXI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXXI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 622 of 754

Table XXXI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXXI-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXXI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-42-1	Et	H	H	H	Bz	H	F	F	OH
XXXI-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXXI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXXI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXXI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXXI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXXI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXXI-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 624 of 754

Table XXXI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXXI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXXI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXXI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 625 of 754

Table XXXI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXXI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXXI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXXII

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 626 of 754

Table XXXII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXXII-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXXII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXXII-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXXII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXXII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXXII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXXII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXXII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXXII-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 628 of 754

Table XXXII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXXII-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXXII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-12-1	Et	H	H	H	Et	H	H	F	OH
XXXII-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXXII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXXII-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXXII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXXII-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXXII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXXII-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 631 of 754

Table XXXII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXXII-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXXII-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXXII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXXII-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXXII-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXXII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXXII-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXXII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXXII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 636 of 754

Table XXXII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXXII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXXII-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXXII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXXII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 639 of 754

Table XXXII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXXII-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXXII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXXII-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXXII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXXII-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXXII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXXII-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXXII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXXII-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-45-8	Ph	*	H	*	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 641 of 754

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXXII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXXII-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXXII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXXII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXXII-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

DOSAGE, ADMINISTRATION, AND USE

A sixth embodiment of the present invention is directed to a composition for the treatment of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, that is intended to include its salts (acid or basic addition salts), hydrates, solvates, and crystalline forms can be obtained, represented by

formula I.

It is contemplated that the formulation of the sixth embodiment can contain any of the compounds contemplated in any of the aspects of the first, second, third, fourth, and fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention.

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions. Compounds of the present invention are efficacious when administered by suppository administration, among other routes of administration. The most convenient manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the severity of the disease and the patient's response to the antiviral medication.

A compound or compounds of the present invention, as well as their pharmaceutically acceptable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as suspensions, emulsions, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is used to prepare a

pharmaceutical composition, and is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound as used herein means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as glycolic acid, pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, salicylic acid, muconic acid, and the like or (2) basic addition salts formed with the conjugate bases of any of the inorganic acids listed above, wherein the conjugate bases comprise a cationic component selected from among Na^+, K^+, Mg^{2+}, Ca^{2+}, and $NH_gR'''_{4-g}{}^+$, in which R''' is a C_{1-3} alkyl and g is a number selected from among 0, 1, 2, 3, or 4. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.

Solid form preparations include powders, tablets, pills, capsules, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders,

preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs and aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Suitable formulations along with pharmaceutical carriers, diluents and expcipients are described in *Remington: The Science and Practice of Pharmacy* **1995,** edited by E.

W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania, which is hereby incorporated by reference. The compounds of the present invention can also be encapsulated in liposomes, such as those disclosed in U.S. Patent Nos. 6,180,134, 5,192,549, 5,376,380, 6,060,080, 6,132,763, each of which is incorporated by reference. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (e.g., salt formulation), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

A seventh embodiment of the present invention is directed to a use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any condition the result of an infection by any one of the following viral agents: hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus.

The term "medicament" means a substance used in a method of treatment and/or prophylaxis of a subject in need thereof, wherein the substance includes, but is not limited to, a composition, a formulation, a dosage form, and the like, comprising the compound of formula **I**. It is contemplated that the compound of the use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any of the antiviral conditions disclosed herein of the seventh embodiment can be any of the compounds contemplated in any of the aspects of the first, second, third, fourth, fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention. A medicament includes, but is not limited to, any one of the compositions contemplated by

the sixth embodiment of the present invention.

A eighth embodiment of the present invention is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective amount of the compound represented by formula I to the subject.

A first aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective of at least two or more different compounds falling within the scope of the compound represented by formula I to the subject.

A second aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least two compounds falling within the scope of the compound represented by formula I to the subject.

It is intended that a subject in need thereof is one that has any condition the result of an infection by any of the viral agents disclosed herein, which includes, but is not limited to, hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus, flaviviridae viruses or pestiviruses or hepaciviruses or a viral agent causing symptoms equivalent or comparable to any of the above-listed viruses.

The term "subject" means a mammal, which includes, but is not limited to, cattle, pigs, sheep, chicken, turkey, buffalo, llama, ostrich, dogs, cats, and humans, preferably the subject is a human. It is contemplated that in the method of treating a subject thereof of the sixth embodiment can be any of the compounds contemplated in any of the aspects of the first, second, and third embodiments or those specifically recited in the tables above, either alone or in combination with another compound of the present invention.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated,

the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.1 and about 10 g, including all values in between, such as 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5, per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.5 and about 7.5 g per day, more preferred 1.5 and about 6.0 g per day. Generally, treatment is initiated with a large initial "loading dose" to rapidly reduce or eliminate the virus following by a decreasing the dose to a level sufficient to prevent resurgence of the infection. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

Therapeutic efficacy can be ascertained from tests of liver function including, but not limited to protein levels such as serum proteins (e.g., albumin, clotting factors, alkaline phosphatase, aminotransferases (e.g., alanine transaminase, aspartate transaminase), 5'-nucleosidase, γ-glutaminyltranspeptidase, etc.), synthesis of bilirubin, synthesis of cholesterol, and synthesis of bile acids; a liver metabolic function, including, but not limited to, carbohydrate metabolism, amino acid and ammonia metabolism. Alternatively the therapeutic effectiveness may be monitored by measuring HCV-RNA. The results of these tests will allow the dose to be optimized.

A third aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of a compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours. Examples of "another antiviral agents" include, but are not limited to: HCV NS3 protease inhibitors (see WO 2008010921, WO 2008010921, EP 1881001, WO

2007015824, WO 2007014925, WO 2007014926, WO 2007014921, WO 2007014920, WO 2007014922, US 2005267018, WO 2005095403, WO 2005037214, WO 2004094452, US 2003187018, WO 200364456, WO 2005028502, and WO 2003006490); HCV NS5B Inhibitors (see US 2007275947, US20072759300, WO2007095269, WO 2007092000, WO 2007076034, WO 200702602, US 2005-98125, WO 2006093801, US 2006166964, WO 2006065590, WO 2006065335, US 2006040927, US 2006040890, WO 2006020082, WO 2006012078, WO 2005123087, US 2005154056, US 2004229840, WO 2004065367, WO 2004003138, WO 2004002977, WO 2004002944, WO 2004002940, WO 2004000858, WO 2003105770, WO 2003010141, WO 2002057425, WO 2002057287, WO 2005021568, WO 2004041201, US 20060293306, US 20060194749, US 20060241064, US 6784166, WO 2007088148, WO 2007039142, WO 2005103045, WO 2007039145, WO 2004096210, and WO 2003037895); HCV NS4 Inhibitors (see WO 2007070556 and WO 2005067900); HCV NS5a Inhibitors (see US 2006276511, WO 2006120252, WO 2006120251, WO 2006100310, WO 2006035061); Toll-like receptor agonists (seeWO 2007093901); and other inhibitors (see WO 2004035571, WO 2004014852, WO 2004014313, WO 2004009020, WO 2003101993, WO 2000006529).

A fourth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of a compound represented by formula **I** and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

A fifth aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of at least one compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in

between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.


A sixth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least one compound represented by formula I and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

It is contemplated that the another antiviral agent includes, but is not limited to interferon -α , interferon-β, pegylated interferon-α, ribavirin, levovirin, viramidine, another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. When the active compound or its derivative or salt are administered in combination with another antiviral agent the activity may be increased over the parent compound. When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the nucleoside derivatives. "Concurrent administration" as used herein thus includes administration of the agents at the same time or at different times. Administration of two or more agents at the same time can be achieved by a single formulation containing two or more active ingredients or by substantially simultaneous administration of two or more dosage forms with a single active agent.


It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions. Furthermore, the term "treatment" of a HCV infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by HCV infection, or the clinical symptoms thereof.

PROCESS FOR PREPARATION

An ninth embodiment of the present invention is directed to a process for preparing the compound of formula I, which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4




5


wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, and base have their meanings as disclosed in the Detailed Description of the Invention and X' is a leaving group, such as Cl, Br, I, tosylate, mesylate, trifluoroacetate, trifluorosulfonate, pentafluorophenoxide, p-NO_2-phenoxide, or other commonly used leaving groups as disclosed in *Advanced Organic Chemistry* by March, Fourth Edition. Leaving groups and methods that can be used to effect the formation of a phosphoramidate nucleoside conjugate are found in US 20060142238 and WO 2007095269. Preferably, the leaving group is Cl.

This reaction is performed in an anhydrous aprotic solvent such tetrahydrofuran, dioxane, or both tetrahydrofuran and dioxane, or any functional equivalent thereof, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, collidine, pyridine, 2,6-lutidine, 2, 6-^{t}Bu-pyridine, etc. a tertiary amine base, such as triethylamine, diisopropylethylamine, etc., or an alkyl Grignard reagent, such as tBuMgCl, tBuMgBr, MeMgCl, MeMgBr, etc. The phosphorochloridate (3-10 equivalents) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

A tenth embodiment of the present invention is directed to a product obtained by a process which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, X', and base have their meanings as disclosed in the Detailed Description of the Invention.

This reaction can be performed in an anhydrous aprotic solvent or other suitable solvent, such as tetrahydrofuran, dioxane, or a mixture of tetrahydrofuran and dioxane, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, a tertiary amine base or tButyl Magnesium Chloride. A phosphorochloridate (3-10 equivalents (or suitable "phosphoro-(leaving group)-date")) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

Compounds and Preparation


Phosphoramidate compounds of the present invention can be prepared by condensation of a nucleoside analog **5** with a suitably substituted phosphochloridate compound **4** (Scheme 1). The nucleoside analog is made by conventional procedures disclosed in any one of U.S. Published Application Nos. 2005/0009737, 2006/0199783,

2006/0122146, and 2007/0197463, each of which is incorporated by reference in its entirety.

Disclosed 1H-NMR values were recorded on a Varian AS-400 instrument. Mass spectral data were obtain using either a Micromass-Quattromicro API or a Waters Acquity.

Thus, by way of example only, a suitably substituted phenol can be reacted with phosphorus oxychloride (**1**) to afford an aryloxy phosphorodichloridate **2** (see Example 1) which is subsequently treated with a acid addition salt of an α-amino acid ester in the presence of TEA to afford an aryloxy phosphorochloridate **4**. This arylalkoxy-amino acid phosphoramidate is reacted with the nucleoside analog to provide the product **I** (for procedure see, e.g., C. McGuigan et al. Antiviral Res. 1992 17:311-321; D. Curley et al. Antiviral Res. 1990 14:345-356; McGuigan et al. Antiviral Chem. Chemother 1990 1(2):107-113).

Scheme 1




The preparation of nucleoside phosphoramidates requires reacting an appropriately substituted phosphochloridate with a nucleoside containing a free 5'-hydroxyl moiety. In cases where only one hydroxyl group is present, preparation of the phosphoramidate usually proceeds smoothly when the phosphochloridate is reacted with the desired nucleoside. In cases where the nucleoside contains more than one free hydroxyl group, preparation of the appropriately protected nucleoside might be required. Silyl, acetonide or other alcohol protecting groups known in the art might be warranted for protection of the sugar moiety. For protection of the nucleoside base, protecting a free amino group may require amidine protection strategy.

Condensation of the phosphochloridate can be carried out on the unprotected nucleoside. Since the 5'-OH group of a nucleoside is much less hindered than the 3'-OH group, selective phosphoramidation is possible under carefully controlled conditions. After condensation to form a protected phosphoramidate nucleoside, deprotection to obtain the free phosphoramidate nucleoside can be carried out using standard protocols for nucleic acid chemistry. In many cases, the desired product is readily separated from the starting material using column chromatography on silica gel. The synthetic scheme is summarized in Scheme 1.

A further understanding of the disclosed embodiments will be appreciated by consideration of the following examples, which are only meant to be illustrative, and not limit the disclosed invention.

EXAMPLE 1

General Procedure for Preparation of phosphorodichloridates




Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 655 of 754

A solution of the appropriate phenol **R^1-OH** (1eq) and triethylamine (1 eq.) in anhydrous ether was added dropwise to a stirred solution of phosphoryl trichloride **1** (1eq) at 0 °C over a period of 3 hours under nitrogen. Then the temperature was warmed to room temperature, and the reaction was stirred overnight. The triethylamine salt was quickly removed with suction filtration and the filtrate concentrated *in vacuo* to dryness to afford **2** as an oil which was used without further purification.

EXAMPLE 2

General Procedure for Preparation of phosphorochloridates




2 **3** **4**

A solution of triethylamine (2eq) in anhydrous dichloromethane was added dropwise to a solution of aryloxy-phosphodichloridate **2** (1 eq) and the appropriate amino ester **3** (1 eq) in anhydrous dichloromethane with vigorous stirring at -78 °C over a period of 30 to 120 minutes. Then the reaction temperature was allowed to warm to room temperature and stirred over night. Solvent was removed. The residue was washed with ethyl ether and filtered, the filtrate was dried over reduced pressure to give **4**.

EXAMPLE 3

General Procedures for nucleoside phosphoramidate derivatives




4 5 I

A solution of the appropriate phosphorochloridate **4** (6.5 equivalents) in anhydrous tetrahydrofuran (THF) was added to a mixture of nucleoside **5** (1 equivalent) and N-methylimidazole (8 equivalents) in anhydrous THF with vigorous stirring at room temperature and the reaction mixture was stirred overnight. The solvent was removed *in vacuo* and the crude was purified by column chromatography and/or preparative thin layer chromatography to give **I**.

EXAMPLE 4

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine



Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 657 of 754

2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (1.0g, 1 eq) (Clark, J., et al., J. Med. Chem., 2005, 48, 5504-5508) was dissolved in 10 ml of anhydrous pyridine and concentrated to dryness in vacuo. The resulting syrup was dissolved in 20 ml of anhydrous pyridine under nitrogen and cooled to 0°C with stirring. The brown solution was treated with benzoyl chloride (1.63g, 3eq) dropwise over 10 min. The ice bath was removed and stirring continued for 1.5h whereby thin-layer chromatography (TLC) showed no remaining starting material. The mixture was quenched by addition of water (0.5 ml) and concentrated to dryness. The residue was dissolved in 50 mL of dichloromethane (DCM) and washed with saturated $NaHCO_3$ aqueous solution and H_2O. The organic phase was dried over $NaSO_4$ and filtered, concentrated to dryness to give N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0 g, Yield: 91%).


N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0g, 1 eq) was refluxed in 80% aqueous AcOH overnight. After cooling and standing at room temperature (15 °C), most of the product precipitated and then was filtered through a sintered funnel. White precipitate was washed with water and co-evaporated with toluene to give a white solid. The filtrate was concentrated and co-evaporated with toluene to give additional product which was washed with water to give a white solid. Combining the two batches of white solid gave 1.50g of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (Yield: 91%).

To a solution of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (1.5 g, 1eq) in MeOH (10 mL) was added a solution of saturated ammonia in MeOH (20mL). The reaction mixture was stirred at 0 °C for 30 min, and then warmed to room temperature slowly. After the reaction mixture was stirred for another 18 hours, the

reaction mixture was evaporated under reduced pressure to give the residue, which was purified by column chromatography to afford pure compound 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (500 mg, Yield: 60 %).

EXAMPLE 5


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate)



Phenyl methoxyalaninyl phosphorochloridate (1 g, 6.5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (50.1 mg, 15.6%). ^{1}H NMR (DMSO-d_6) δ 1.20-1.27 (m, 6H), 3.58 (d, J = 16.0 Hz, 3H), 3.75-3.92 (m, 2H), 4.015-4.379 (m, 2H), 5.54 (t, J = 10.2 Hz, 1H), 5.83-5.91 (m, 1H), 6.00-6.16 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.22 (s, 1H), 7.35 (t, J = 4.4 Hz, 2H), 7.55 (s, 1H), 11.52 (s, 1H); MS, *m/e* 502 $(M+1)^+$.

EXAMPLE 6


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate)



Phenyl methoxy-valyl phosphorochloridate (0.6 g, 3.6 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.44 g, 9 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (60 mg, 20%). ^{1}H NMR (DMSO-d_6) δ 0.74-0.847 (m, 6H), 1.20-1.28 (m, 3H), 1.89-1.92 (m, 1H), 3.50-3.54 (m, 1H), 3.58 (d, J = 10.4Hz, 3H), 3.72-3.95 (m, 1H), 4.03-4.05 (m, 1H), 4.23-4.43 (m, 2H), 5.56 (t, J = 16.0 Hz, 1H), 5.85-5.92 (m, 1H), 6.01-6.07 (m, 1H), 7.16-7.21 (m, 3H), 7.37 (t, J = 8 Hz, 2H), 7.55-7.60 (m, 1H), 11.52 (s, 1H); MS, *m/e* 530 $(M+1)^+$.

EXAMPLE 7


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate)



4-Bromophenyl methoxy-valyl phosphorochloridate (1 g, 3.4 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.2 g,1 eq) and N-methylimidazole (0.35 g, 6 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed reduced pressure to give the desired product (120 mg, 26%). ^{1}H NMR (DMSO-d_6) δ 0.72-0.82 (m, 6H), 1.19-1.26 (m, 3H), 1.86-1.92 (m, 1H), 3.48-3.50 (m, 1H), 3.56 (d, J = 12.0 Hz, 3H), 3.72-3.89 (m, 1H), 3.96-4.03 (m, 1H), 4.22-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.85-5.91 (m, 1H), 5.98-6.13 (m, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.49-7.56 (m, 3H), 11.53 (s, 1H); MS, *m/e* 608 $(M+1)^+$.

EXAMPLE 8


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate)



4-Bromophenyl methoxy-alanyl phosphorochloridate (0.6 g, 5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq)and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (40 mg, 12 %); ^{1}H NMR (DMSO-d_6) δ 1.20-1.26 (m, 6H), 3.57 (d, J = 2.8 Hz, 3H), 3.84 (s, 1H), 3.97-4.03 (m, 1H), 4.21-4.25 (m, 1H), 4.33-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.83-5.89 (m, 1H), 5.98-6.19 (m, 1H), 7.16 (t, J = 10.2 Hz, 2H), 7.52-7.57 (m, 3H), 11.52 (s, 1 H); MS, *m/e* 580(M+1)$^+$.

EXAMPLE 9

Preparation of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine




2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (500 mg, 1.9 mmol) was stirred with dimethylformamide dimethyl acetal in DMF (10 mL). The resulting mixture was

stirred at room temperature overnight. After solvent removal the crude product was used for next step without further purification.

EXAMPLE 10


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-alanyl phosphate)



Phenyl methoxyalaninyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (62 mg, 20.6%). ^{1}H NMR (DMSO-d_6) δ 1.16 (d, J = 23.2 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H), 3.56 (S, 3H), 3.69-3.75 (d, J = 25.6 Hz, 1H), 3.82-3.86 (m, 1H), 3.96-3.98 (m, 1H), 4.21-4.34 (m, 2H), 5.68 (d, J = 7.2 Hz, 1H), 5.75-5.77 (m, 1H), 6.07-6.16 (m, 1H), 7.15-7.19 (m, 3H), 7.2 (d, J = 9.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.48 (d, J = 9.2 Hz, 1H); MS, *m/e* 501(M+1)$^+$.

EXAMPLE 11

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1.0 g, 3.4 eq.) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.2 g,1 eq.) and N-methylimidazole (0.35 g, 6 eq.) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (59 mg, 13%); ^{1}H NMR (DMSO-d_6) δ 0.74-0.83 (m, 6H), 1.12-1.20 (m, 3H), 1.89-1.92 (m, 1H), 3.49-3.51 (m, 1H), 3.55 (s, 3H), 3.59-3.68 (m, 1H), 3.72-.383 (m, 1H), 4.21-4.39 (m, 2H), 5.70-5.72 (m, 1H), 5.76-5.83 (m, 1H), 6.04-6.16 (m, 1H), 7.15 (d, J = 13.0 Hz, 2H), 7.26 (s, 1H), 7.33 (s, 1H), 7.46-7.55 (m, 1H), 7.56 (d, J = 4.4 Hz, 2H) ; MS, *m/e* 607 $(M+1)^+$.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 664 of 754

EXAMPLE 12

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate)




Phenyl methoxy-valyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (86 mg, 42.9 %). ^{1}H NMR (DMSO-d_6) δ 0.72-0.80 (m, 6H), 1.09-1.18 (m, 3H), 1.87-1.92 (m, 1H), 3.47-3.51 (m, 1H), 3.58 (s, 3H), 3.71-3.75 (m, 1H), 3.97 (t, J = 11.2 Hz,1H), 4.22-4.37 (m, 2H), 5.70 (d, J = 8.0 Hz,1H), 5.76-5.84 (m, 1H), 6.01-6.15 (m, 1H), 7.13-7.18 (m, 3H), 7.27 (s, 2H), 7.34 (d, J = 4.0 Hz, 2H), 7.46-7.50 (m, 1H); MS, *m/e* 529 $(M+1)^+$.

EXAMPLES

Example numbers **13-54** and **56-66** are prepared using similar procedures described for examples **5-8.** The example number, compound identification, and NMR/MS details are shown below:

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 665 of 754



Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
13	Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.16 (m, 3H), 1.20-1.28(m,6H), 3.70-3.90 (m, 2H), 4.00-4.08 (m, 3H), 4.18-4.45 (m, 2H), 5.52-5.58 (m, 1H), 5.85-5.98 (m, 1H), 6.00-6.20 (m, 2H), 7.16-7.23 (m, 3H), 7.37-7.40 (m, 2H) , 7.54-7.60 (m, 1H), 11.54 (s.1H) ; MS, m/e 516.1 (M+1)+
14	1-Napth	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.18-1.30 (m, 6H), 3.78-4.10 (m, 3H), 4.38-4.49 (m, 2H), 4.99-5.11 (m, 2H), 5.28-5.40 (m, 1H), 5.85-6.10 (m, 2H), 6.30-6.41 (m, 1H), 7.28-7.32 (m, 5H), 7.41-7.60 (m, 5H), 7.73-7.76(m, 1H), 7.94-8.11(m, 1H), 8.13-8.15(m, 1H), 11.50 (s.1H) ; MS, m/e 628.4 (M+1)+
15	Ph	H	H	H	Me	1H NMR (DMSO-d_6) δ 1.22 (d, J=22.4 Hz, 3H), 3.59(s, 3H), 3.63-3.69 (m, 2H), 3.74-3.8(m, 1H), 4.02(d, J=11.2 Hz, 1H), 4.23-4.28(m, 1H), 4.40-4.43 (m, 1H), 5.57-5.60 (m, 1H), 5.89(d, J=6.8 Hz, 1H), 6.00-6.06(m, 2H), 7.15-7.23 (m, 3H), 7.35-7.39 (m, 2H),7.52(d, J=8 Hz, 1H), 11.52(s, 1H) ; MS, m/e 487.97 (M+1)+
16	2,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.57-3.60 (m, 3H), 3.84-3.92 (m, 2H), 4.00-4.04 (m, 1H), 4.31-4.44 (m, 2H), 5.54-5.61 (m, 1H), 5.85-6.10 (m, 2H), 6.32-6.43 (m, 1H), 7.44-7.54 (m, 3H), 7.72-7.75 (m, 1H), 11.54 (s.1H) ; MS, m/e 570.2 (M+1)+
17	1-Napth	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.15-1.27 (m, 6H), 3.51-3.55 (d, 3H), 3.85-3.96 (m, 2H), 4.00-4.10(m, 1H), 4.30-4.46 (m, 2H), 5.31-5.39 (m, 1H), 5.89-6.05 (m, 2H), 6.22-6.34 (m, 1H), 7.44-7.60 (m, 5H), 7.73-7.77 (m, 1H), 7.93-7.96 (m, 1H), 8.12-8.14 (m, 1H),11.50(s.1H) ; MS, m/e 552.1 (M+1)+
18	Ph	*	H	*	Me	1H NMR (DMSO-d_6) δ 1.19 (d, J=22.8 Hz, 3H), 1.69-1.84 (m, 3H), 1.99-2.04 (m, 1H), 3.16-3.21 (m, 2H), 3.58 (s, 3H), 3.68-3.8 (m, 1H), 4.00 (m, 1H), 4.01-4.13 (m, 1H), 4.22-4.25 (m, 1 H), 4.5 (d, J = 11.2 Hz, 1H), 5.54 (d, J = 8.0 Hz, 1H), 5.86 (s, 1H), 5.6 (d, J = 19.6 Hz, 1H), 7.15-7.2 (m, 3H), 7.34 (t, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 1H), 11.38 (s, 1H) ; MS, m/e 527.93(M+1)+
19	Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.80-0.90 (m, 3H), 1.20-1.35 (m, 8H), 1.48-1.55 (m, 2H), 3.78-3.88 (m, 2H), 3.95-4.08 (m, 3H), 4.22-4.45 (m, 2H), 5.55-5.57(t, 1H), 5.85-6.18 (m, 3H), 7.14-7.23 (m, 3H), 7.35-7.40 (m, 2H), 7.51-7.60 (d, 1H), 11.50 (s.1H) ; MS, m/e 544.2 (M+1)+
20	Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.20-1.30 (m, 6H), 3.72-4.05 (m, 3H), 4.23-4.27 (m, 1H), 4.32-4.45 (m, 1H), 5.07-5.10(t, 2H), 5.52-5.56(t, 1H), 5.86-6.10 (m, 2H), 6.13-6.21(m,1H), 7.15-7.21 (m, 3H), 7.29-7.40 (m, 7H), 7.51-7.56 (d, 1H), 11.50 (s.1H) ; MS, m/e 578.2 (M+1)+
21	4-F-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.28-1.34 (m, 6H), 3.65(d, J= 4 Hz, 3H), 3.85-3.96 (m, 2H), 4.06-4.12 (m, 1H), 4.30-4.34 (m,1H), 4.40-4.47 (m, 1H),

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						5.62-5.67 (m, 1H), 5.94-6.01(m, 1H), 6.09 (d, J=18.8 Hz, 1H), 6.17-6.26 (m, 1H), 7.27-7.33(m, 4H), 7.62 (d, J = 7.6 Hz, 1H), 11.61 (s, 1H) ; MS, m/e 519.94(M+1)+
22	4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.58 (d, 2H), 3.70-3.95(m,2H), 3.95-4.08 (m,1H), 4.23-4.45 (m, 2H), 5.55-5.61(t, 1H), 5.85-6.10 (m, 2H), 6.15-6.23(m,1H), 7.20-7.26 (m, 2H), 7.43-7.46 (m, 2H), 7.54-7.57 (d, 1H), 11.50 (s.1H) ; MS, m/e 536.1 (M+1)+
23	3,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.13 (m, 6H), 3.49 (s, 3H), 3.61-3.85 (m, 2H), 3.90-3.93 (m, 1H), 4.16-4.22 (m, 1H), 4.27-4.31 (m, 1H), 5.47-5.52 (m, 1H), 5.82 (d, J = 11.6 Hz, 1H), 5.93(d, J = 19.2 Hz, 1H), 6.15-6.25 (m, 1H), 7.13 (t, J = 9.6 Hz, 1H), 7.43 (d, J = 12Hz, 2H), 7.57 (d, J = 6.0 Hz, 1H), 11.43(s, 1H) ; MS, m/e 569.85 (M+1)+
24	Ph	H	H	Me	2-Bu	1H NMR (DMSO-d_6) δ 0.83 (d, J = 6.8 Hz, 6H), 1.20-1.26 (m, 6H), 1.79-1.86 (m, 1H), 3.73-3.90 (m, 4H), 4.01 (t, J = 11.2 Hz, 1H), 4.21-4.28 (m, 1H), 4.33-4.42 (m, 1H), 5.54 (t, J = 7.6 Hz, 1H), 5.85-5.92 (m, 1H), 5.99-6.13 (m, 2H), 7.19 (t, J = 8 Hz, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 11.52 (s, 1H) ; MS, m/e 544.00 (M+1)+
25	Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.28 (m, 12H), 3.74-3.81 (m, 2H), 3.95-4.08 (m,1H), 4.20-4.45 (m, 2H), 4.83-4.87 (m, 1H), 5.52-5.58 (m, 1H), 5.84-6.15 (m, 3H), 7.17-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.54-7.57 (m, 1H), 11.50 (s.1H) ; MS, m/e 530.2 (M+1)+
26	4-MeO-Ph	H	H	Me	n-Bu	1HNMR (400MHz, DMSO-d_6): δ =0.78-0.82 (m, 3H), 1.29-1.47 (m, 8H), 1.49-1.54 (m, 2H), 3.66-3.87 (m, 5H), 3.96-4.02 (m, 3H), 4.21-4.39 (m, 2H), 5.57 (t, J= 12.0Hz, 1H), 5.84-6.05 (m, 3H), 6.90 (dd, J1 =8.0Hz, J2=4.0Hz, 2H), 7.09-7.14 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.55 (d, J =8.0Hz, 1H), 11.48-11.62 (s, 1H)
27	4-F-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.28 (m, 9H), 3.72-3.94(m,2H) ,3.98-4.10 (m,3H), 4.21-4.42(m,2H), 5.55-5.61 (t, 1H), 5.85-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 533.90 (M+1)+
28	4-F-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.30 (m, 12H), 3.74-3.85(m,2H) ,3.98-4.06 (m,1H), 4.23-4.41(m,2H), 4.83-4.87 (m, 1H), 5.55-5.61 (t, 1H), 5.85-6.12 (m, 3H), 7.18-7.24 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 547.91 (M+1)+
29	4-F-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.10-1.23 (m, 6H), 3.65-3.89(m,3H) ,4.10-4.30 (m,2H), 4.96-5.00(m,2H), 5.46-5.50 (t, 1H), 5.75-5.96 (m, 2H), 6.04-6.12(m,1H), 7.05-7.11 (m,4H), 7.20-7.24 (d, 5H), 7.42-7.45(d,1H), 11.50 (s.1H) ; MS, m/e 595.94 (M+1)+
30	4-MeO-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ=1.15-1.27 (m, 12H), 3.71-3.89 (m, 5H), 3.98-4.02 (m, 1H), 4.22-4.25 (m, 1H), 4.33-4.39 (m, 1H), 4.84-4.87 (m, 1H), 5.57 (t, J= 12.0Hz, 1H), 5.91-6.03 (m, 3H), 6.90 (d, J= 8.0Hz, 2H), 7.09-7.14 (m, 2H), 7.55 (d, J= 8.0Hz, 1H), 11.51 (s, 1H)
31	2-Cl-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.23 (m, 6 H), 3.93-4.00 (m, 3 H), 4.27-4.40 (m, 2H), 5.0(t, J= 7.2 Hz, 2 H), 5.53 (m ,1 H), 5.80-6.0(m , 2 H), 6.30(m, 1H), 7.15 (d, J= 2.4 Hz, 1 H), 7.27 (m, 6 H), 7.51 (m, 3 H), 11.5 (s, 1 H) ; MS, m/e 579.87(M+1)+ / 596.78 (M+18)+

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
32	2,4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ=0.82 (m, 3 H),1.23 (m, 8 H) , 1.47 (m, 2 H), 3.86 (m, 2 H), 3.84 (m, 3 H),4.27-4.43 (m, 2H), 5.5 (m , 1 H), 6.02 (m ,2 H), 6.35(m, 1H), 7.44 (m, 3 H), 7.77 (m, 1 H), 11.5 (s, 1 H) ; MS, m/e 611.87(M+1)+
33	4-Me-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.14-1.27 (m, 12H), 2.17-2.26 (m, 3H), 3.73-3.82 (m, 1H), 3.99-4.02 (m, 1H), 4.23-4.26 (m, 1H), 4.37-4.40 (m, 1H), 4.82-4.88 (m, 1H), 5.52-5.58 (m, 1H), 5.85-6.07 (m, 3H), 7.01-7.20 (m, 4H), 7.55 (d, J = 16Hz, 1H), 11.51 (s, 1H) ; MS, m/e 543.98 (M+1)+; 1108.86 (2M+23)+
34	4-F-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.82-0.89 (m,3H), 1.20-1.31 (m, 8H), 1.48-1.53 (m,2H), 3.77-3.90 (m,2H) ,3.95-4.10 (m,3H), 4.21-4.45(m,2H), 5.56-5.61 (t, 1H), 5.83-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 584.1 (M+23)+
35	3,4-diCl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ1.12-1.31 (m, 9H), 3.77-3.92 (m,2H), 3.95-4.08 (m,3H), 4.21-4.45(m,2H), 5.56-5.62 (t, 1H), 5.80-6.11 (m, 2H), 6.18-6.33(m,1H), 7.18-7.25 (m,1H), 7.49-7.56 (d, 2H), 7.62-7.67(m,1H), 11.50 (s.1H) ; MS, m/e 606.1 (M+23)+
36	2-Cl-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ =1.12-1.16 (m, 6H), 1.21-1.27 (m, 6H), 3.79-3.85 (m, 2H), 4.00-4.07 (m, 1H), 4.28-4.32 (m, 1H), 4.38-4.43 (m, 1H), 4.83-4.87 (m, 1H), 5.56 (dd, J1=16.0Hz, J2=8.0Hz, 1H), 5.85-6.12 (m, 2H), 6.20-6.33 (m, 1H), 7.19-7.22 (m, 1H), 7.33 (t, J= 16.0Hz, 1H), 7.48-7.55 (m, 3H), 11.55 (s, 1H)
37	4-MeO-Ph	H	H	Me	Bn	1HNMR(400MHz, DMSO-d_6): δ=1.19-1.26 (m, 6H), 3.69-3.70 (s, 3H), 3.87 (m, 2H), 3.99 (m, 1H), 4.20-4.21 (m, 1H), 4.35 (m, 1H), 5.07-5.09 (m, 2H), 5.54 (t, J = 16.0Hz, 1H), 5.85-5.92 (m, 1H), 6.04-6.10 (m, 2H), 6.86 (d, J= 8.0Hz, 2H), 7.09 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.30-7.34 (m, 5H), 7.53 (s, 1H), 11.52 (s, 1H)
38	Ph	H	H	Me	n-Pen	1H NMR (DMSO-d_6) δ 0.79-0.81 (m, 3H), 1.17-1.23 (m, 10H), 3.74-3.81 (m, 2H), 3.94-3.96 (m, 3H), 4.19-4.36 (m, 2H), 5.49-5.54 (m, 1H), 5.87-6.08 (m,3H), 7.14-7.33 (m, 3H), 7.31-7.35 (m, 2H), 7.51 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 557.9 (M+1)+; 1136.88 (2M+23)+
39	4-Cl-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.04-1.19 (m, 12H), 3.76-3.80 (m , 2H), 3.98-4.08 (m, 1H), 4.42-4.42 (m, 2H), 4.82-4.85 (m, 1H), 5.55-5.60 (m, 1H), 5.80-6.20 (m,3H),7.20-7.2 5(m, 2H), 7.43 (d, J = 8.8Hz, 1H), 7.54 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 563.88 (M+1)+; 1148.73 (2M+23)+
40	4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.85 (t, J = 7.2 Hz, 3H), 1.22-1.33 (m, 8H),1.45-1.53 (m, 2H), 3.80-3.87 (m, 2H), 3.96-4.04 (m, 3H), 4.24-4.27 (m, 1H), 4.35-4.39 (m, 1H), 5.56-5.61 (m, 1H), 5.82-6.11 (m, 2H), 6.15-6.18 (m, 1H), 7.20-7.56 (m, 4H), 7.51-7.57 (m.1H) , 11.54 (s, 1H); MS, m/e577.95(M+1)+
41	4-Cl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.14 (t, J = 7.0Hz, 3H), 1.20-1.28 (m, 6H),3.77-3.88 (m, 2H), 3.99-4.07 (m, 3H), 4.24-4.28 (m, 1H), 4.34-4.43 (m, 1H), 5.56-5.61 (m, 1H), 5.86-6.13 (m, 2H), 6.15-6.24 (m, 1H), 7.20-7.26 (m, 2H), 7.44 (d, J = 7.6Hz, 2H) , 7.55 (d, J = 7.6Hz,

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						1H), 11.55 (s, 1H); MS, m/e549.11(M+1)+
42	4-Me-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.79-0.83 (m, 3H), 1.17-1.28 (m, 8H), 1.45-1.47 (m, 2H), 2.22 (d, J = 2.8Hz, 1H), 3.70-3.90 (m, 2H), 3.95-3.98 (m, 3H), 4.10-4.40 (m, 2H), 5.51 (t, 1H), 5.80-5.90 (m, 1H), 5.95-6.05 (m, 2H), 7.02-7.06 (m, 2H), 7.51 (t, J = 4.2Hz , 4H), 7.51 (d, 1H), 11.51 (s, 1H) ; MS, m/e 557.99(M+1)+; 1136.84(2M+23)+
43	4-Me-Phe	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.16-1.24 (m, 6H), 2.22 (s , 3H), 3.65-4.03 (m,3H), 4.11-4.38 (m, 2H), 5.04-5.05 (m, 2H), 5.48-5.50 (m, 1H), 5.77-5.87 (m,1H),5.90-6.11 (m, 2H), 6.98-7.10 (m, 4H), 7.28-7.32 (m, 5H), 7.50 (t ,1H), 11.48 (s, 1H) ; MS, m/e 592.00 (M+1)+.
44	Ph	H	H	Et	Me	1H NMR (DMSO-d_6) δ 0.70-0.80 (m, 3H), 1.11-1.26 (m, 3H), 1.42-1.61 (m, 2H), 3.50-3.54 (m, 3H), 3.58-3.80 (m, 2H), 3.91-4.02 (m, 1H), 4.12-4.38 (m, 2H), 5.47-5.52 (m,1H),5.90-6.03 (m, 2H), 7.08-7.16 (m, 3H), 7.26-7.35 (m, 2H),7.48 (t,1H),11.45 (s, 1H) ; MS, m/e 515.95 (M+1)+; 1052.82 (2M+23)+
45	Ph	H	H	Me	4-F-Bn	^{1}HNMR (400MHz, DMSO-d_6): δ 1.20-1.26 (m, 6H), 3.80-3.93 (m, 2H), 3.98 (s, 1H), 4.25-4.26 (m, 1H), 4.36-4.37 (m, 1H), 5.07 (s, 2H), 5.52-5.55 (m, 1H), 5.86-5.87(m, 1H), 5.98-6.04 (m, 1H), 6.14-6.17 (m, 1H), 7.15-7.20 (m, 5H), 7.36 (dd, *J* = 20.0, 8.0 Hz, 4H), 7.54 (s, 1H), 11.55 (s, 1H)
46	4-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 1.21-1.28 (m, 6H), 3.71-3.88 (m, 1H), 3.91-3.98 (m, 1H), 4.00-4.01 (m, 1H), 4.23-4.27 (m, 1H), 4.35-4.38 (m, 1H), 5.08 (d, *J* = 4.0Hz, 2H), 5.57 (dd, *J* = 12.0, 8.0 Hz, 1H), 5.91 (d, *J* = 8.0 Hz, 1H), 6.01 (d, *J* = 8.0 Hz, 1H), 6.22-6.24 (m, 1H), 7.17-7.23 (m, 2H), 7.31-7.40 (m, 7H), 7.53 (s, 1H), 11.50 (s, 1H)
47	Ph	H	H	Me	3-Me-1-Bu	^{1}H NMR (DMSO-d_6) δ 0.80-0.82 (m, 6H), 1.18-1.40 (m, 8H), 1.50-1.58 (m, 1H), 3.71-3.82 (m, 3H), 3.97-3.4.01 (m, 3H), 4.21-4.40 (m, 2H), 5.30(t, *J* = 8.6 Hz, 1H), 5.81-6.10 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.48 (d, *J* = 8.4 Hz, 1H), 11.38 (s, 1H) ; MS, *m/e* 557.98 $(M+1)^+$; 1136.88 $(2M+23)^+$
48	3,4-diCl-Ph	H	H	Me	Bn	^{1}H NMR (DMSO-d_6) δ 1.05-1.37 (m, 6H), 3.71-3.82 (m, 1H), 3.87-4.02 (m, 2H), 4.28-4.29 (m, 1H),4.36-4.38 (m, 1H),5.04 (d, *J* = 5.2Hz, 2H), 5.55-5.64 (m, 1H), 5.85-5.94 (m, 1H), 6.00-6.05 (m, 1H), 6.29-6.40 (m, 1H),7.17-7.24 (m, 1H), 7.30-7.41 (m, 5H), 7.45-7.58 (m, 2H), 7.61 (d, *J* = 4.0Hz, 1H), 11.53 (s, 1H); MS, *m/e*545.80$(M+1)^+$;
49	Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.18-1.41 (m, 12H), 1.59-1.67 (m, 4H), 3.74-13.80 (m, 1H), 3.96-4.02 (m, 1H), 4.19-4.26 (m, 1H), 4.31-4.39 (m, 1H), 4.60 (s, 1H), 5.52 (t, *J* = 7.8 Hz, 1H), 5.80-6.09 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.52 (d, *J* = 8 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 569.98 $(M+1)^+$; 592.14 $(M+23)^+$
50	Ph	H	Me	H	n-Bu	1H NMR (DMSO-d_6) δ 0.76 (t, J = 7.2Hz, 3H), 1.10-1.22 (m, 8H), 1.38-1.43 (m, 2H), 3.72-3.75 (m, 2H), 3.87-3.93 (m, 3H), 4.14-4.21 (m, 1H), 4.23-4.33 (m, 1H), 5.46-5.54 (m, 1H), 5.84-6.11 (m, 3H), 7.09-7.14 (m, 2H), 7.27-7.32 (m, 2H), 7.34-7.51 (m, 1H), 11.47 (s, 1H); MS, m/e543.98(M+1)+
51	Ph	H	Me	H	i-Pr	1H NMR (DMSO-d_6) δ 1.39 (d, J = 7.2Hz, 6H), 1.19-1.29 (m, 6H),

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						3.65-3.75 (m, 2H), 3.95-4.05 (m, 1H), 4.20-4.22 (m, 1H), 4.31-4.33 (m, 1H), 4.79-4.82 (m, 1H), 5.48-5.57 (m, 1H), 5.84-5.91 (m, 1H), 5.96-6.07 (m, 2H), 7.12-7.35 (m, 5H), 7.44-7.54 (m.1H), 11.49(s, 1H); MS, m/e529.96 (M+1)+
52	Ph	H	Me	H	Bn	^{1}H NMR (DMSO-d_6) δ 1.18-1.28 (m, 6H), 3.70-3.83 (m, 1H), 3.87-3.94 (m, 1H), 3.99-4.01 (m, 1H), 4.23-4.26 (m, 1H), 4.33-4.37 (m, 1H), 5.03-5.12 (m, 2H), 5.51-5.59 (m, 1H), 5.87-5.90 (m, 1H), 5.95-6.07 (m, 1H), 6.10-6.27 (m, 1H), 7.15-7.23 (m, 3H), 7.31-7.38 (m, 7H), 7.47-7.56 (m, 1H), 11.50 (s, 1H); MS, m/e577.99 (M+1)+
53	2-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 0.81-0.86 (m, 3H), 1.21-1.31 (m, 8H), 1.46-1.52 (m, 2H), 3.84-3.90 (m, 2H), 3.97-4.04 (m, 3H), 4.27-4.41 (m, 2H), 5.53-5.58 (m, 1H), 5.82-5.95 (m, 1H), 5.96-6.10 (m, 1H), 6.27-6.31 (m, 1H), 7.19-7.22 (m, 1H), 7.34 (dd, J = 8.0, 4.0 Hz, 1H), 7.47-7.55 (m, 3H), 11.55 (s, 1H)
54	4-Br-Ph	H	H	Me	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ 1.10-1.14 (m, 6H), 1.20-1.27 (m, 6H), 3.74-3.81 (m, 2H), 3.99-4.01 (m, 1H), 4.21-4.25 (m, 1H), 4.37-4.38 (m, 1H), 4.81-4.85 (m, 1H), 5.58 (dd, J = 8.0, 4.0 Hz, 1H), 5.82-5.95 (m, 1H), 5.96-6.09 (m, 1H), 6.10-6.13 (m, 1H), 7.18 (dd, J = 12.0, 8.0 Hz, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H)
55	4-F-Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.20-1.44 (m, 12H), 1.60-1.71 (m, 4H), 3.75-4.02 (m, 2H), 3.94-4.02 (m, 1H), 4.19-4.26 (m, 2H), 4.59-4.61 (m, 1H), 5.57 (t, J = 8.4 Hz, 1H), 5.85-6.06 (m, 3H), 7.17-7.23 (m, 4H), 7.54 (d, J = 8.4 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 587.92 $(M+1)^+$
56	4-Br-Ph	H	H	Me	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ =1.18-1.46 (m, 12H), 1.61-1.69 (m, 4H), 3.75-3.82 (m, 2H), 3.95-4.08 (m, 1H), 4.25-4.28 (m, 1H), 4.38 (s, 1H), 4.60-4.62 (m, 1H), 5.56-5.60 (m, 1H), 5.82-5.95 (m, 1H), 6.02-6.20 (m, 2H), 7.09-7.20 (m, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H) MS, *m/e* 650.0 $(M+3)^+$
57	Ph	H	H	Et	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ =0.75-0.82 (m, 3H), 1.12-1.26 (m, 9H), 1.52-1.59 (m, 2H), 3.55-3.68 (m, 1H), 3.72-3.85 (m, 1H), 3.95-4.08 (m, 1H), 4.18-4.28 (m, 1H), 4.32-4.41 (m, 1H), 4.83-4.86 (m, 1H), 5.55 (m, J= 7.6Hz, 1H), 5.99-6.04 (m, 2H), 6.05-6.10 (m, 1H), 7.14-7.21 (m, 3H), 7.33-7.37 (m, 2H), 7.52-7.54 (m, 1H), 11.53 (s, 1H) ; MS, *m/e*566.07$(M+23)^+$
58	Ph	H	H	Et	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ 0.75-0.88 (m, 3H), 1.26-1.46 (m, 9H), 1.52-1.69 (m, 6H), 3.60-3.63 (m, 1H), 3.72-3.90 (m, 1H), 4.02-4.03 (m, 1H), 4.24-4.27 (m, 1H), 4.37-4.38 (m, 1H), 4.63-4.65 (m, 1H), 5.55 (dd, J =8.0Hz, 4.4Hz, 1H), 5.80-5.95 (m, 1H), 6.00-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.34-7.38 (m, 2H), 7.54 (d, J =8.0Hz, 1H), 11.55 (s, 1H); MS, *m/e* 584.01 $(M+1)^+$, 606.17 $(M+23)^+$
59	4-F-Ph	H	H	Et	c-Hex	^{1}H NMR (DMSO-d_6) δ 0.75-0.84 (m, 3H), 1.24 (d, J = 22.8Hz, 3H), 1.29-1.47 (m, 6H), 1.51-1.70 (m, 6H), 3.59-3.66 (m, 1H), 3.77-3.84 (m, 1H), 3.98-4.04 (m, 1H), 4.21-4.27 (m, 1H), 4.34-4.41 (m, 1H), 4.60-4.65 (m, 1H), 5.56-5.60 (m, 1H), 5.84-5.90 (m, 1H), 6.00-6.08

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						(m, 2H), 7.20-7.24 (m, 4H), 7.56(d, *J* = 8.0Hz, 1H), 11.49 (s, 1H); MS, *m/e* 602.00(M+1)$^+$
60	Ph	H	H	Me	F-CH_2-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.18-1.25(m, 6H), 3.71-3.89 (m, 2H), 3.92-3.99 (m, 1H), 4.19-4.27 (m, 4H), 4.48-4.61 (m, 2H) , 3.94-3.98 (m, 2H), 4.11-4.23 (m, 4H), 5.47-5.52 (m, 1H), 6.01-6.11 (m, 1H), 5.90-6.14 (m, 2H), 7.15-7.21 (m, 3H), 7.32-7.36 (m, 2H), 7.46-7.57 (m, 1H), 11.49 (s,1H) ; MS, *m/e* 533.86 (M+1)$^+$
61	Ph	H	H	Me	F_2CH-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.17-1.24 (m, 6H), 3.67-3.81 (m, 1H), 3.89-3.98 (m, 2H),4.21-4.36 (m, 4H), 5.48-5.53 (m, 1H), 5.82-6.05 (m, 2H), 6.18-6.22 (m, 2H), 7.15-7.20 (m, 3H), 7.32-7.36 (m , 2H), 7.51 (s, 1H),11.50 (s, 1H) ; MS, *m/e* 551.92 (M+1)$^+$;
62	Ph	H	H	Me	$(CF_3)_2$-CH-	^{1}H NMR (DMSO-d_6) δ 1.13-1.29 (m, 6H), 3.67-3.81 (m, 1H), 3.94-4.32 (m, 4H), 5.47 (t, *J* = 8 Hz 1H), 5.82-6.01 (m, 2H), 6.33-6.36 (m, 1H), 6.70-6.78 (m, 1H), 7.09-7.15 (m, 3H), 7.28-7.32 (m , 2H), 7.43-7.46 (m, 1H),11.44 (s, 1H) ; MS, *m/e* 637.90 (M+1)$^+$
63	Ph	H	H	Me	$(CH_2F)_2$ -CH-	^{1}H NMR (DMSO-d_6) δ 1.20-1.29 (m, 6H), 3.70-3.90 (m, 1H), 3.91-4.12 (m, 2H), 4.20-4.33 (m, 1H), 4.35-4.48 (m, 1H), 4.52-4.55 (m, 2H), 4.63-4.67 (m, 2H), 5.20-5.35 (m, 1H), 5.56 (t, *J* = 8.4 Hz, 1H), 5.80-5.95 (m, 1H), 5.95-6.10 (m, 1H), 6.18-6.21 (m, 1H), 7.18-7.23 (m, 3H), 7.35-7.39 (m , 2H), 7.54 (s, 1H),11.55 (s, 1H) ; MS, *m/e* 565.98 (M+1)$^+$
64	Ph	H	H	Me	c-Pr-CH_2-	^{1}H NMR (DMSO-d_6) δ 0.20-0.24(m, 2H), 0.47-0.48(m, 2H), 0.76-0.84(m, 3H), 1.03-1.05(m, 1H), 1.23(dd, *J= 22.4 6.8 Hz* 3H), 1.55-1.60(m, 2H), 3. 61-3.68(m, 1H), 3. 81-3.89 (m, 3H), 3.98-4.03(m, 1H), 4.23-4.29(m, 1H), 4.35-4.41(m, 1H), 5.56-6.00(m, 1H), 5.88-5.91(m, 1H), 6.04-6.10(m, 2H), 7.20-7.24(m, 4H), 7.55 (d, *J= 7.6 Hz* 1H),11.53 (s, 1H) ; MS, *m/e* 573.17 (M+1)$^+$
65	Ph	H	H	Et	c-Pen	^{1}H NMR (DMSO-d_6) δ 0.75-0.83 (m, 3H), 1.20-1.28 (m, 3H), 1.49-1.63 (m, 8H), 1.76-1.80 (m, 2H), 3.58-3.60 (m, 1H), 3.70-3.82 (m, 1H), 3.98-4.05 (m, 1H), 4.24-4.26 (m, 1H), 4.37-4.42 (m, 1H), 5.03 (s, 1H), 5.54-5.57 (m, 1H), 5.90-6.00 (m,1H), 6.02-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.35-7.39 (m, 2H) 7.55 (d, *J* = 8.0 Hz, 1H), 11.55 (s, 1H) ; MS, *m/e* 570.03 (M+1)$^+$

*R^2 and R^{3b} together are –$(CH_2)_3$– as derived from L-proline

The purification procedure by Prep-HPLC:

Crude products were dissolved in methanol. Injection volumes of these solutions were 5 mL.

The preparative HPLC system including 2 sets of Gilson 306 pumps, a Gilson 156 UV/Vis detector, a Gilson 215 injector & fraction collector, with Unipoint control software. A Ymc 25×30×2 mm column was used. The mobile phase was HPLC grade water (A), and HPLC grade acetonitrile (B). Fractions were collected into 100*15mm glass tubes.


HPLC gradient is shown in Table 1. Once the gradient was selected, acetonitrile solution was injected into HPLC system, and then fractions collected according to UV peaks. After the separation, each glass tubes were run MS test to collect the desired compounds. The fractions with target MS were combined in a well-weighted flask. Most of acetonitrile was removed under reduce pressure and the remaining solution was freeze-dried to give desired compound.

Table 1:

Preparative HPLC gradient			
Time (min)	Flow rate (mL/min)	% A	% B
0	15	90	10
30	15	60	40

Preparation of Example 66

Scheme



Preparation of compound (b)

To a solution of compound **a** (1 g, 2.69 mmol) in anhydrous THF (30 mL) was added dropwise 1 M solution of LiAl(OBu-*t*)$_3$H in THF (2.69 mL, 2. 69 mmol) at -20 °C. The reaction mixture was stirred for 2-3 h at the same temperature. EtOAc (100 mL) was added followed by saturated NH_4Cl solution (10 mL) and reaction mixture was slowly brought to room temperature. Reaction mixture was extracted with EtOAc and washed with 1N HCl and water. Combined organic phase was evaporated to give 0.8 g of crude compound **b** as transparent oil, which was used directly for next reaction.

Preparation of compound (d)

To a solution of compound **b** (0.8 g, 2.1mmol), compound **c** (0.45 g, 2.5 mmol) and Ph_3P (0.56 g, 2.1 mmol) in anhydrous THF (20 mL) under nitrogen atmosphere was added DEAD (1.8 mL). The reaction mixture was stirred at room temperature overnight.

The reaction solution was concentrated under reduce pressure. The residue was separated by preparative layer chromatography (hexanes:EtOAc = 3:1) to give crude compound **d** (0.8 g). The crude compound **d** was used to the next step without further purification.

Preparation of compound (e)

Compound **d** (0.8 g, 1.57 mmol) was dissolved in THF (2 mL) and THF saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was heated to 90 °C overnight. After 18 hours, the solution was cooled to room temperature by ice water, then the solvent was removed under reduced pressure and the residue was purified by column to give compound **e** (0.75 g) for the next step.

Preparation of compound (f)

Compound **e** (0.5 g, 1.01 mmol) was dissolved in methanol (2 mL) and methanol was saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was stirred at room temperature overnight. After 18 hours, the solvent was removed under reduced pressure and the residue was purified by column to give crude compound **f** (0.15 g) for the next step.

Preparation of compound (i)


A solution of triethylamine (1.07 g, 10.6 mmol) in anhydrous dichloromethane (15 mL) was added dropwise to a solution of compound **g** (1.16 g, 5.3 mmol) and compound **h** (1.31 g, 5.3 mmol) in dichloromethane (10 mL) with vigorous stirring at -78 °C over a period of 2 hours. After completion of addition, the reaction temperature was allowed to warm to room temperature gradually and stirred over night. Then the solvent was removed under vacuum and anhydrous ether 20 mL was added and the precipitated salt was filtered and the precipitate was washed with ether. The combined organic phase was concentrated to give the colorless oil of compound **i** (1.0 g).


Preparation of Compound 66


To a solution of compound **j** (0.1 g, 0.35 mmol) dissolved in 10 mL of anhydrous THF, stirred and added 0.4g NMI till the solution became clear, added compound **i** (0.8 g, 2.89 mmol) in 10 mL THF dropwise, stirred at r.t. overnight. Compound purity and identification was confirmed by LCMS. The solvent was evaporated and purified by Prep-HPLC to afford **66**. (25 mg, Yield: 13.6%). ^{1}H NMR (DMSO-d_6) δ 1.08 (d, J = 22.8 Hz, 3H), 1.17-1.24 (m, 3H), 3.50-3.52 (m, 3H), 3.78-3.83 (m, 1H), 4.10-4.13 (m,

1H), 4.24-4.44 (m, 2H), 5.85-5.92 (m, 1H), 6.01-6.11 (m,1H), 6.2.-6.27 (m, 1H), 7.08-7.19 (m, 4H), 7.31-7.38 (m, 3H), 8.15 (s, 1H), 8.26 (s, 1H); MS, *m/e* 525 $(M+1)^+$.


Example numbers **67-74**, identified below, were prepared using similar procedures disclosed for Example **66**, above.






Example	R^{11}	R^{10}	NMR/MS
67	OH	NH_2	^{1}H NMR (DMSO-d_6) δ 1.06-1.13 (m, 3H), 1.20-1.24 (m, 3H), 3.27-3.33(m, 3H), 3.56 (s, 1H), 3.82-3.88 (m, 1H), 4.07-4.13 (m, 1H), 4.25-4.40 (m, 2H), 5.85-5.87 (m, 1H), 5.98-6.09 (m, 2H), 6.59 (s, 32H), 7.14-7.37 (m, 3H), 7.35-7.37 (m, 2H), 7.79 (d, *J*=7.2 Hz, 1H), 10.69 (s, 1H); MS, *m/e* 541 $(M+1)^+$;
68	NH_2	NH_2	^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.8 Hz, 3H), 1.19 (d, *J*=7.2 Hz, 3H), 3.51 (s, 3H), 3.62 (s, 1H), 3.75-3.81 (m, 1H), 4.05-4.11 (m, 1H), 4.27-4.42 (m, 2H), 5.79-5.83 (m, 1H), 5.92 (s, 2H), 6.00-6.09 (m, 2H), 6.75 (s, 2H), 7.08-7.17 (m, 3H), 7.31-7.35 (m, 2H), 7.78 (s, 1H); MS, *m/e* 540 $(M+1)^+$;
69	NH_2	c-Pentyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.05 (d, *J*=22.8 Hz, 3H), 1.09-1.19 (m, 3H), 1.48 (s, 4H), 1.66 (s, 1H), 1.86 (s, 1H), 3.54 (d, *J*=14 Hz, 3H), 3.65 (s, 1H), 4.25-4.43 (m, 4H), 5.71-5.82 (m, 1H), 5.94-6.04 (m, 4H), 7.11-7.24 (m, 3H), 7.26-7.34 (m, 2H), 7.77(d, *J*=3.6 Hz, 1H); MS, *m/e* 608$(M+1)^+$
70	NH_2		^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.4 Hz, 3H), 2.35-2.38 (m, 2H), 3.54 (d, *J*=9.2 Hz, 3H), 3.59-3.62 (m, 2H), 3.65 (s, 1H), 3.75-3.82 (m, 1H), 4.01-4.13 (m, 2H), 4.22-4.40 (m, 6H), 5.75-5.85 (m, 1H), 6.00-6.07 (m, 4H), 7.15-7.21 (m, 3H), 7.32-7.35 (m, 2H), 7.79 (d, *J*=4.0 Hz, 1H); MS, *m/e* 580 $(M+1)^+$
71	NH_2	Et_2N-	^{1}H NMR (DMSO-d_6) δ 1.06-1.28 (m, 12H), 3.55 (d, *J*=4.8 Hz, 3H), 3.79-3.87 (m, 4H), 4.07-4.12 (m, 2H), 4.29-4.42 (m,

Example	R^{11}	R^{10}	NMR/MS
			3H), 5.75-5.82 (m, 1H), 5.94 (s, 2H), 6.04-6.10 (m, 2H), 7.14-7.22 (m, 3H), 7.31-7.37 (m, 2H), 7.82 (d, *J*=4.4 Hz, 1H); MS, *m/e* 596 $(M+1)^+$
72	NH_2	n-Propyl-NH-	^{1}H NMR (DMSO-d_6) δ 0.84 (t, *J*=7.2 Hz, 3H), 1.01-1.01 (m, 3H), 1.09-1.12 (m, 3H), 1.51-1.56 (m, 2H), 3.48 (d, *J*=15.2 Hz, 3H), 3.79-3.82 (m, 1H), 4.04-4.05 (m, 1H), 4.27-4.38 (m, 3H), 5.72-5.79 (m, 1H), 5.98-6.04 (m, 4H), 7.13-7.20 (m, 3H), 7.26-7.32 (m, 2H), 7.76 (d, *J*=5.2 Hz, 1H); MS, *m/e* 582 $(M+1)^+$
73	NH_2	c-Butyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.02-1.08 (m, 3H), 1.18 (d, *J*=4.8 Hz, 3H), 1.44-1.61 (m, 2H), 2.02-2.17 (m, 4H), 3.51 (d, *J*=10.8 Hz, 3H), 3.78-3.83 (m, 1H), 4.03-4.06 (m, 1H), 4.27-4.38 (m, 2H), 4.53-4.62 (m, 1H), 5.68-5.79 (m, 1H), 5.95-6.04 (m, 4H), 7.11-7.18 (m, 3H), 7.29-7.35 (m, 2H), 7.51-7.58 (m, 1H), 7.78 (d, *J*=5.2 Hz, 1H); MS, *m/e* 594 $(M+1)^+$
74	NH_2		^{1}H NMR (DMSO-d_6) δ 0.97-1.20 (m, 6H), 2.18 (s, 3H), 2.19 (s, 4H), 3.43-3.47(m, 3H), 3.75 (s, 1H), 4.01-4.06 (m, 4 H), 4.22-4.35 (m, 3H), 5.69-5.75 (m, 1H), 5.98-6.05 (m, 3H), 7.09-7.15 (m, 3H), 7.25-7.29 (m, 2H), 7.77 (d, *J*=3.6 Hz, 1H); MS, *m/e* 623 $(M+1)^+$

Example numbers 75-80 are prepared using similar procedures disclosed for Example **66**, above.



Example	R^{11}	R^{10}
75	H	n-propyl-NH-
76	H	c-Butyl-NH-
77	H	c-Pentyl-NH-
78	H	
79	H	
80	H	

EXAMPLE 81

Certain exemplified compounds were obtained as mixture of diastereomers because of the chirality at phosphorous. The diastereomers were separated on a Chiralpak-AS-H (2 X 25 cm) column under Supercritical Fluid Chromatography (SFC) conditions using 20% methanol in carbon dioxide as solvent. The absolute stereochemistry of the P-chiral center of the diastereromers were not determined. However, chromatographic resolution of these two diastereomers provides for isomers that are characterized as fast eluting and slow eluting isomers. Some examples are shown below.

Compound	EC90 (uM)
Example 15 (Diastereomeric mixture)	0.86
Fast Moving isomer of **Example 15**	1.35
Slow Moving isomer of **Example 15**	0.26
Example 39 (Diastereomeric mixture)	0.47
Fast Moving isomer of **Example 39**	0.78
Slow Moving isomer of **Example 39**	0.02

Compound	EC90 (uM)
Example 49 (Diastereomeric mixture)	0.126
Fast Moving isomer of **Example 49**	0.03
Slow Moving isomer of **Example 49**	5.78








EXAMPLE 82







HCV replicon assay. HCV replicon RNA-containing Huh7 cells (clone A cells; Apath, LLC, St. Louis, Mo.) were kept at exponential growth in Dulbecco's modified Eagle's medium (high glucose) containing 10% fetal bovine serum, 4 mM L-glutamine and 1 mM sodium pyruvate, 1× nonessential amino acids, and G418 (1,000 μg/ml). Antiviral assays were performed in the same medium without G418. Cells were seeded in a 96-well plate at 1,500 cells per well, and test compounds were added immediately after seeding. Incubation time 4 days. At the end of the incubation step, total cellular RNA was isolated (RNeasy 96 kit; Qiagen). Replicon RNA and an internal control (TaqMan rRNA control reagents; Applied Biosystems) were amplified in a single-step multiplex RT-PCR protocol as recommended by the manufacturer. The HCV primers and probe were designed with Primer Express software (Applied Biosystems) and covered highly conserved 5′-untranslated region (UTR) sequences (sense, 5′-AGCCATGGCGTTAGTA(T)GAGTGT-3′, and antisense, 5′-TTCCGCAGACCACTATGG-3′; probe, 5′-FAM-CCTCCAGGACCCCCCCTCCC-TAMRA-3′).







To express the antiviral effectiveness of a compound, the threshold RT-PCR cycle of the test compound was subtracted from the average threshold RT-PCR cycle of the no-drug control (ΔCt_{HCV}). A ΔCt of 3.3 equals a 1-log 10 reduction (equal to the 90% effective concentration [EC_{90}]) in replicon RNA levels. The cytotoxicity of the test compound could also be expressed by calculating the ΔCt_{rRNA} values. The ΔΔCt specificity parameter could then be introduced ($\Delta Ct_{HCV} - \Delta Ct_{rRNA}$), in which the levels of

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 678 of 754

HCV RNA are normalized for the rRNA levels and calibrated against the no-drug control.

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11
10		-1.25	19.15
11		-0.55	ND
12		0.31	ND

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
15		ND	0.86
25		-2.22	0.39
27		-2.25	0.66
28		-2.16	0.75
36		-1.64	21.9
39		-1.78	0.47

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
49		-2.69	0.126
53		-1.33	<0.3
54		-1.55	0.57
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3


[1](4-BrPh): 4-bromo-phenyl.

The entire contents of U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, are hereby incorporated by reference in the present application so far as needed to supplement the present disclosure and/or rectify any errors. Moreover, the patent and non-patent references disclosed herein are incorporated by reference. In the event that the incorporated patent and non-patent reference contains a term that conflicts with a term disclosed in either one of the two Provisional Applications or the present application text, the meaning of the term contained in the present application text and the two Provisional Applications controls provided that the overall meaning of the incorporated subject matter is not lost.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 682 of 754

We claim:

1. A compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 683 of 754

includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl,substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 684 of 754

alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-

C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

2. A compound its stereoisomer, salt, hydrate, solvate, or crystalline form thereof selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N*,*N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

3. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 695 of 754

alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -N($R^{3'}$)$_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -(CH_2)$_p$OH, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 696 of 754

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

4. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N*,*N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 698 of 754

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 699 of 754

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 705 of 754

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

5. A use of the compound represented by formula I in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

wherein the compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, are represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;


(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a b c d

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$,

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 709 of 754

$CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

6. A use of

a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-

yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

7. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of the compound represented by formula I to the subject;

wherein the compound or its stereoisomer, salt, hydrate, solvate, or crystalline form thereof represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 718 of 754

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is


H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 720 of 754

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

8. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 721 of 754

hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

9. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 730 of 754

Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$

alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};


R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R',

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) $–C=CH_2$, or (iii) $–NO_2$;

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

10. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N*,*N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 737 of 754

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**




4




5

11. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 741 of 754

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or

alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or -N($R^{3'}$)$_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -(CH_2)$_p$OH, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), OS(O)$_2$(C_{1-4} acyl), OS(O)$_2$(C_{1-4} alkyl), OS(O)$_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 743 of 754

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 744 of 754


of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$

and


wherein X' is a leaving group, such as, Cl.

12. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5 ;

wherein the product comprises a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-

pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N*,*N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

wherein Base' is as recited in each of compounds 5-74; and

wherein X' is a leaving group, such as, Cl.

ABSTRACT

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:



I

Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Atea Pharmaceuticals, Inc.
Exhibit 1014 Page 754 of 754